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Abstract
Niemann-Pick type-C disease is a rare autosomal recessive neurodegenerative disease that
classically presents in the first decade, leading to ataxia, vertical-gaze palsy, loss of
communication skills, epileptic seizures, and eventually death. The stark reality about NPC
disease underlines the important role the NPC1 protein plays in whole-body lipid
homeostasis. It is no surprise, then, that the NPC1 gene has been associated with other
diseases as well, such as obesity, diabetes, and Ebola virus infection. In this manuscript, a
connection will be made that intertwines genetics, biochemical and molecular mechanisms,
physiology, and evolutionary pressures, and will explain how a gene, discovered for its
contribution to a devastating disease, may unlock a new understanding of human
metabolism.
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Chapter 1: Introduction: a history of Niemann-Pick type-C

Niemann-Pick Disease: a history
Niemann-Pick disease was first characterized and publicized by the German physician
Albert Niemann in his article, "An unknown clinical picture," in 1914 [1]. Years later, German
pathologist Ludwig Pick released a series of papers describing the pathology of the disease in the
1930s [2]. These doctors focused on the initial symptoms of the disease, hepatosplenomegaly in
child patients, and its later manifestation, neurodegeneration in adolescents, working to
understand why these seemingly healthy children suddenly fell ill and died. For their work, the
disease was named after them. Both doctors also noted the fact that it tended to segregate to
certain ethnic backgrounds. With time, different clinical presentations of Niemann-Pick disease
were identified: types A, B, C, and D. Eventually, types A and B were found to be due to
sphingomyelinase deficiency and types C and D were determined to be due to a defect in NPC1
and NPC2 function.
Drs. Niemann and Pick recognized that, based on their experiences, this disease was
apparent predominantly in German Jewish populations [3]. The underlying reason for this being
that 95% of the occurrence of Niemann-Pick type-C disease is due to an autosomal recessive
mutation in the eponymously named NPC1 gene [4]; hence, a rare disease-causing allele is more
likely to be combined into a single genome (i.e. one disease-presenting child) within a population
that has similar genetic history. Albert Niemann and Ludwig Pick were obviously unaware of the
underlying genetic machinery that they were observing; but, nonetheless, their foundational work
understanding the pathology pushed future researchers to understand the biochemical processes
for this devastating disease.
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It is clear now that the NPC1 protein plays a pivotal role in the egress of low-densitylipoprotein (LDL) derived cholesterol and lipids from the late endosome/ lysosome to the sterol
pool of the cell [5]. When a person has two copies (one maternal, one paternal) of a diseasecausing mutation in the NPC1 gene, they are unable to express functional NPC1 protein. The
lack of functional NPC1 protein leads to accumulation of cholesterol and other lipids in the
lysosome. This accumulation leads to downstream detrimental changes in the processing of LDL
as well as attenuation of sphingomyelinase activity [6]. These downstream effects are thought to
contribute to the loss of the myelin sheath surrounding neurons, characteristic of this disease [7].
Neurodegeneration tends to begin in the first decade of life, leading to ataxia, vertical-gaze palsy,
loss of communication skills, epileptic seizures, and eventually death. The stark reality about
NPC disease underlines the important role the NPC1 protein plays in whole-body lipid
homeostasis. It is no surprise, then, that the NPC1 gene has been associated with other diseases,
such as obesity, diabetes, and, more recently, Ebola virus infection. In this manuscript, a
connection will be made that intertwines genetics, biochemical and molecular mechanisms,
physiology, and evolutionary pressures, and will explain how a gene, discovered for its
contribution to a devastating disease, may unlock a new understanding of human metabolism.
Discovering the NPC1 gene and uncovering the NPC1 protein’s biochemical role
Soon after the advent of the Human Genome Project, researchers raced to discover the
chromosomal locus that contained the NPC1 gene. Through a collaborative effort, a group of
researchers published an article in 1997 describing the gene’s location and the proposed 1278
amino acid protein that it encodes [5]. In the article, the researchers also note the NPC1 protein’s
homologous motifs with similar structures to sterol regulatory element binding protein (SREBP)
cleavage-activating protein, SCAP, as well as with 3-hydroxy-3-methyl-glutaryl coenzyme A
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(HMG-CoA) reductase. These homologous motifs hold important clues to the understanding of
NPC1’s biochemical function. Soon after this article, it became clear that cells lacking functional
NPC1 protein exhibited a significant accumulation of unesterified cholesterol [8], which is not
surprising due to the protein’s homology to SCAP and HMG-CoA reductase, two proteins well
known for their function in cholesterol homeostasis. What is also interesting, is that gangliosides
(a type of sphingolipid) were found to accumulate in NPC1 deficient fibroblasts in the presence
of progesterone, which would explain the progression of Niemann-Pick disease in the presence
of the hormonal increase, characteristic of pubescence [9]. Colocalizing NPC1 protein with the
cholesterol-accumulating lysosome was necessary at this point to confirm its effects, and was
carried out in the year 2000 [10]. From this work, it appears that NPC1 transiently associates
with the late endosome/ lysosome but is predominantly found to colocalize to a novel
compartment. It is hypothesized that this novel compartment serves as a cellular mechanism for
lipid homeostasis and membrane maintenance. The transient association can be increased if the
cells are incubated with LDL or progesterone, confirming earlier findings. Lipid accumulation in
cells lacking functional NPC1 protein was found to be because of NPC1’s role in trafficking
cholesterol and other lipids to the endoplasmic reticulum (ER), trans-Golgi network, as well as
the plasma membrane [11]. Once LDL derived cholesterol has been delivered to the ER it can
inhibit SREBP activation by maintaining the complex formed with SCAP [12]. At this point the
NPC1 gene is downregulated, due to feedback inhibition from the SREBP protein’s deactivation
[13]. There is a sterol regulatory element (SRE) upstream from the promoter region of the NPC1
gene. Lack of mature SREBP in the nucleus leads to decreased NPC1 expression. With all of this
in mind, NPC1’s role in lipid homeostasis has become clearer. It is integral to exogenous
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cholesterol and lipids that enter hepatocytes through LDL-receptor mediated endocytosis being
properly trafficked to downstream signaling molecules.
Investigating obesity
In the year 2009, NPC1 gene variants were found to be associated with increased risk for
obesity in French populations [14]. This association caused NPC1 to be designated an obesity
risk candidate gene. Since that designation, NPC1 has been confirmed to be associated with
obesity in Chinese, Danish, Mexican and New Zealand populations [15]–[18]. It was with this in
mind that our lab set out to determine the mechanism responsible for NPC1’s contribution to
obesity. Our work began with the establishment of the NPC1 obesity mouse model. This model
involves using the heterozygous NPC1+/- mouse. The heterozygous mice exhibit 50% gene
dosage, which theoretically simulates an amplified model of the common risk-associated human
NPC1 variants. To clarify, the human NPC1 loss-of-function variants are thought to decrease
NPC1 activity, albeit, to a lesser degree than that observed in the heterozygous mouse model.
When these mice are fed a high fat diet, they gain weight significantly more than normal mice
[19]. This is the first documented case of a gene-diet interaction. Upon delving deep into the
physiology and biochemistry of the NPC1+/- mouse, we were able to characterize a functional
pathway that demonstrates how NPC1 contributes to obesity. This work is fully documented in
Chapter 2. Once we identified a mechanism, our goal was to translate what we had shown in
mice to humans, as well as confirm the previously documented associations within our local
New Mexican population. Chapter 3 contains the detailed description of that work. Taking into
consideration the work we and other groups had previously reported, the pathway we described,
and our translational work confirming the pathway in humans, we believe NPC1 is the most well
documented and highly understood obesity risk candidate gene of all those discovered to date.
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Evolution of metabolic gene variants
The existence of a gene variant that predisposes one to obesity has been the root of much
controversy for the last 50 years. The idea that a variant can be detrimental to its host and yet be
so common in the majority of human populations seems to fly in the face of evolutionary theory,
at first glance. Many have proposed hypotheses, but, by far, the most influential was the Thrifty
Gene hypothesis, proposed by James Neel in 1963 [20]. In this groundbreaking article, Neel
proposed that the selective pressures of famine in generations past have shaped the genome to
include genes that are “thrifty,” that is, they are very efficient at maintaining energy stores when
calories are scarce or non-existent. This, in turn, predisposes humans to obesity in an
environment where calories are practically infinite, or far exceeding what is necessary for basic
metabolic needs. While the merits and minutiae of this hypothesis have been heavily debated,
with its detractors and its champions, the elegant manner with which it describes the human
condition cannot be denied.
Opinions on the matter will likely never reach a unified consensus, due to the
controversial nature of the topic; however, we have provided evidence which we believe
characterizes Neel’s hypothesis as overly simplistic yet vindicated. The details of this work are
laid out in Chapter 4. Briefly, we have identified global changes in human obesity risk variant
frequencies after migration from Africa which provide evidence for two environments that
selected for thrifty genes: the early hunter-gatherer lifestyle which selected for ancestral risk
alleles, and the later agricultural revolution which, due to famine caused by crop failures,
selected for derived risk alleles. We believe, since the NPC1 human obesity risk alleles are
ancestral, that they were likely selected for in the hunter-gatherer environment, which explains
why they are so common in modern humans.

5

Conclusion
The pivotal role of NPC1 in human homeostasis and metabolism cannot be understated.
The lack of functional NPC1 protein leads to a disastrous childhood mortality. Loss-of-function
mutations in the human gene lead to increased risk of developing the metabolic diseases of
obesity and diabetes. And yet, those very same mutations may have been responsible for the
success of early humans to hunt prey on the savannahs of Africa 200,000 years ago. We may
owe our very existence to mutations which, now, are the cause of our suffering. But perhaps the
improved and expanded knowledge of our weaknesses will provide us with a road map to
navigate away from diets and behaviors we know to interact with our specialized metabolism.
When we understand what makes us vulnerable to disease, perhaps we can arm ourselves with
steadfast resolutions that will guide us into a future where obesity and diabetes enter a remission
not yet seen in the modern age.
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Abstract
A genome-wide association study has reported that the human Niemann-Pick C1 gene
(NPC1) is associated with common adult obesity. These findings were confirmed using our
BALB/cJ Npc1 mouse model whereby heterozygous mice (Npc1+/-) possessing decreased gene
dosage were susceptible to weight gain when fed a high-fat diet compared to homozygous
normal mice (Npc1+/+) fed the same diet. The objective for this study was to validate this genediet interaction and define the physiological mechanism responsible for weight gain. Statistical
modeling using fitted growth trajectories indicated that Npc1+/- mice are susceptible to weight
gain when fed a high-fat, but not when fed a low-fat diet, compared to Npc1+/+ mice fed the
same diets, thereby confirming a gene-diet interaction. However, comprehensive metabolic
phenotype analysis indicated that food/water intake, oxygen consumption, carbon dioxide
production, locomotor activity, adaptive thermogenesis, and intestinal fat absorption were similar
between Npc1+/+ and Npc1+/- mice when fed a low-fat or high-fat diet. Nonetheless, we
determined that livers from Npc1+/- mice had significantly increased amounts of mature sterol
regulatory element-binding protein-1 (SREBP-1) and associated increase in expression of target
genes for hepatic lipogenesis using RNA microarray analysis. Furthermore, white adipose tissue
from Npc1+/- mice had significantly decreased amounts of phosphorylated (activated) hormone
sensitive lipase (HSL) and impaired triacylglycerol mobilization. Finally, cellular energy
metabolism studies indicated that Npc1+/- fibroblasts have significantly increased basal
glycolysis but significantly decreased basal oxidative metabolism resulting in an accumulation of
neutral lipid. In conclusion, the Npc1 gene interacts with a high-fat diet to alter key energy
metabolism pathways.
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Introduction
The human Niemann-Pick C1 gene (NPC1) has been primarily investigated in relation to
a rare autosomal-recessive lipid-storage disorder characterized by hepatosplenomegaly and
progressive neurological degeneration that often results in death during the second decade (9,
17). The NPC1 gene is localized to chromosome 18 and encodes a complex membrane-bound
protein that has extensive structural homology with members of the resistance-nodulationdivision (RND) family of prokaryotic permeases (5, 6). With respect to the principal structural
motifs, the NPC1 protein contains 13 membrane-spanning helices and 3 large luminal domains
among which an N-terminal domain (NTD) and sterol-sensing domain (SSD) independently bind
cholesterol (18, 36). Although exact function of the NPC1 protein remains undefined, studies
indicate that the NPC1 protein has a central role in regulating the transport of lipid substrates
(cholesterol, fatty acid, or sphingosine) across the limiting membrane of late endosomes into the
cytoplasm (5, 29, 40). As a result the characteristic phenotype for both cultured cells and tissues
deficient in NPC1 protein function is an accumulation of these lipids in late endosomes and
lysosomes (40, 44). A more recent study indicates that the SSD forms a cavity in membrane
bilayers and is capable of accommodating one cholesterol molecule consistent with this
structural motif serving as both a lipid sensing and transport domain (26). With respect to
expression of the NPC1 gene it has been reported to be primarily regulated through the sterol
regulatory element-binding protein (SREBP) pathway, consistent with the NPC1 protein having
a central role in maintaining cellular, tissue, and whole body lipid homeostasis (11, 13). Further
studies have also indicated that the mouse Npc1 gene is regulated by fatty acids, but surprisingly
not cholesterol, through feedback inhibition of the SREBP-1 pathway (22).
A genome-wide association study (GWAS) has revealed that the human NPC1 gene is also
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associated with morbid-adult obesity in European populations (32). This study was performed
using nearly 1,400 obese Europeans compared to a similar number of age-matched normal
weight controls and confirmed with an additional 2,100 obese and 2,400 normal weight
individuals. When this particular study was published it was unknown whether the NPC1 gene
ancestral risk variants (644A>G encoding His215Arg and 2572A>G encoding Ile858Val)
increased or decreased NPC1 protein function. To address this question and further investigate
the NPC1 gene in relation to weight gain, we performed growth studies using the BALB/cJ Npc1
mouse model possessing a retroposon insertion that prematurely terminates protein translation,
thereby producing a non-functional truncated NPC1 protein (10, 15, 31). The results from this
study demonstrated that compared to Npc1 homozygous normal (Npc1+/+) mice, the Npc1
heterozygous (Npc1+/-) mice with decreased gene dosage are susceptible to excessive weight
gain when fed a high-fat diet but not when fed a low-fat diet (23). This study was later extended
using BALB/cJ-C57BL/6J hybrid Npc1+/- mice that were also susceptible to weight gain and
impaired glucose tolerance when fed a high-fat diet compared to hybrid Npc1+/+ mice fed the
same diet (24). And most recently, we reported that C57BL/6J Npc1+/- mice are susceptible to
weight gain when fed a high-fat diet compared to C57BL/6J Npc1+/+ mice fed the same diet (21).
Together, these results and an independent mouse GWAS using more than 100 strains of mice
indicate that multiple Npc1 gene variants interact with a high-fat diet to increase body fat
percentage and weight gain (39).
It is believed that gene-environment interactions, in particular gene-diet interactions, have
a central role in propagating the worldwide epidemic of obesity (3, 37). The concept of a genediet interactions serve as a focal point for the evolutionary origins of obesity in different
populations that occur through neutral and positive selection (45). To date, approximately 130
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human obesity genes have been identified and believed to interact with a dietary component to
promote weight gain (30). This being true, recent population-based studies to identify and
quantify gene-diet interactions for obesity have resulted in low effect sizes due in part to limited
validity of food questionnaires and ability to perform deep phenotype analysis (4, 33). Therefore,
the objective for this study was to determine the physiological basis for how decreased Npc1
gene dosage in mice, which closely phenocopies human NPC1 gene risk variants, interacts with a
high-fat diet to promote weight gain.

Materials and methods
Mouse model. A breeding pair of BALB/cNctr-Npc1m1N/J mice (hereafter referred to as
Npc1 mice) was obtained from the Jackson Laboratory and maintained at the University of New
Mexico Health Sciences Center in accordance with the Institutional Animal Care and Use
Committee (Animal Welfare Assurance A3350-01 and USDA Registration 85-R-0014). Mice
were bred to generate Npc1 homozygous normal mice (Npc1+/+) and Npc1 heterozygous mice
(Npc1+/-), whereby the latter mice are characterized with decreased gene dosage and express onehalf the normal amounts of functional NPC1 protein in all tissues and isolated fibroblasts (10,
41). The Npc1+/+ and Npc1+/- mice were housed in a room maintained at 24-25C, 31-32%
humidity, with an alternating 12 h light and dark cycle.

Mouse diets. At the time of weaning (4 weeks of age) the male Npc1+/+ and Npc1+/- mice
were fed either a low-fat diet (4.0% g fat and 0.00% g cholesterol; D07021301) or a high-fat diet
(24% g fat and 0.02% g cholesterol; D07021302) with water ad libitum. This low-fat diet (LFD)
and high-fat diet (HFD) are energy balanced diets (same total % energy) formulated and
produced by Research Diets. A semi-synthetic high-fat diet containing 5% fat in the form of
14

sucrose polybehenate (D07031502) was also formulated and produced by Research Diets and fed
to mice to measure intestinal fat absorption. The composition and fatty acid profile of these
mouse diets are available upon request. The mice were weighed on a weekly basis from 4-20
weeks of age to obtain body weights for growth study analysis.

Growth data analysis. The growth data represents repeated measures on the weights of 58
male mice (29 Npc1+/+ mice and 29 Npc1+/- mice) from 4 to 20 weeks of age as previously
described (23). The mice were selected from 27 different litters (varying in size from 2 to 10
mice) on the basis of an Npc1+/+ or Npc1+/- genotype and randomized among 18 cages to receive
a LFD or HFD. The fitted growth trajectories for the four groups of mice were modeled using a
mixed effects regression model fitted to the weight data over time using Stata Statistical
Software as previously described (43). The specific model used for the fitted growth trajectories
is available upon request.

Physical and biochemical analyses. The mice were food deprived (4-5 hours) and
sacrificed using CO2 asphyxiation at 20 weeks of age to obtain terminal body weights, tissue
weights, and plasma. The collected tissues and plasma were frozen in liquid nitrogen for
molecular and biochemical analyses. The liver lipids were extracted using an organic solvent,
separated using thin layer chromatography (TLC), and the amount of lipids (cholesterol,
cholesteryl ester, free fatty acid, and triacylglycerol) were measured as previously described
(20). The amount of liver lipids was normalized to the amount of liver protein precipitated during
extraction to determine tissue concentration. The concentration of plasma cholesterol,
triacylglycerol, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were
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determined using the Infinity Cholesterol, Triacylglycerol, ALT, and AST kits (Thermo
Scientific) as previously described (20). The concentration of energy regulating hormones
(insulin and cortisol) and inflammatory cytokines (IL-1, IL-6, and TNF-) were determined
using the appropriate mouse Insulin ELISA kit (ALPCO), Cortisol EIA kit (Cayman Chemical),
and Ready-SET-Go cytokine kits (eBioscience). The normal control serum (Data-Trol N) and
abnormal control serum (Data-Trol A) (Thermo Scientific) were used as negative and positive
controls.
Metabolic phenotype analysis. A separate group of Npc1+/+ and Npc1+/- mice were
generated from the same colony and sent to the Seattle Mouse Metabolic Phenotyping Center
(MMPC) at the University of Washington Health Sciences Center to perform metabolic
phenotype analysis. The body composition, intake of food and water, and key determinants of
energy expenditure (oxygen consumption, carbon dioxide production, locomotor activity, and
heat production) during the 12-h light and dark cycles were measured after fed a LFD (10 weeks
of age) followed by a HFD for 9 days (11 weeks of age). Metabolic phenotype analysis was
performed at this intermediate age (10-11 weeks of age instead of 30 weeks of age) to prevent
confounding variables possibly resulting from excessive weight gain and metabolic disease. The
body composition studies were determined using quantitative magnetic resonance (Echo Medical
Systems) which measured both lean body mass and fat body mass of anaesthetized mice (46).
The rates of oxygen consumption, carbon dioxide production, activity, and heat production were
measured continuously by indirect calorimetry over 36 h using the Comprehensive Lab Animal
Monitoring System (Columbus Instruments.

Intestinal fat absorption and fecal lipid content. The non-invasive measurement of
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intestinal fat absorption was measured as previously described (19). Mice were fed a LFD from 4
to 10 weeks of age followed by a HFD containing 5% fat in the form of sucrose polybehenate
which is a non-absorbable food additive for a period of 4 days. The fecal pellets were collected
on days 3 and 4. Fat absorption was calculated from the ratio of behenic acid to other fatty acids
present in the diet and feces analyzed using gas chromatography of fatty acid methyl esters at the
Cincinnati Mouse Metabolic Phenotypic Center. The mice used for non-invasive measurement of
intestinal fat absorption were also fed a HFD for 10 days followed by fecal pellets being
collected and measured gravimetrically as previously described (42). The fecal lipids were
extracted using hexane:isopropanol (3:1) and allowed to dry. The dried lipid extract was
suspended into 1 ml of chloroform containing 2% Triton X-100 and evaporated overnight. The
pellet residue was suspended into 0.5 ml of water and solubilized overnight at 4ºC. The lipid
content (cholesterol, triacylglycerol, and free fatty acids) was measured using the Infinity
Cholesterol and Infinity Triacylglycerol kits (Thermo Scientific), and the EnzyChrom Free Fatty
Acid kit (BioAssay Systems).

Measurement of adipose lipolysis. The Npc1+/+ and Npc1+/- mice were fed a HFD until 10
weeks of age. Adipose lipolysis was measured using inguinal white adipose tissue (WAT)
explants. The excised tissue was equilibrated overnight in Dulbecco’s Modified Eagle Medium
(DMEM) and cut into portions (0.10-0.15 g) followed by incubation in DMEM with or without
1.0 μM isoproterenol for 3 h which activates the adipose tissue -adrenergic receptor to mobilize
lipid stores (1). After incubation, the glycerol content of the medium was measured using the
Free Glycerol Reagent quantitative enzymatic assay (Sigma).
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Fibroblast glycolytic metabolism and oxidative metabolism. Mouse fibroblasts were
derived from the peritoneal membrane of Npc1+/+ and Npc1+/- mice and maintained in basic
media (DMEM, 5.5 mM glucose, and 10% FBS). Fibroblasts were seeded into 24-well culture
plates (5x105 cells/well) and incubated for 24 h before placed into the SeaHorse XF24
Extracellular Analyzer used to determine the i) extracellular acidification rate (ECAR) which is a
measure of glycolytic metabolism (flux of glucose substrate through the glycolysis pathway) and
ii) oxygen consumption rate (OCR) which is a measure of oxidative metabolism (flux of glucose
and fatty acid through the mitochondrial tricarboxylic acid cycle and electron transport chain).
To determine OCR of endogenous fatty acids stored in the form of triacylglycerol, basic media
was exchanged for substrate-limited media (DMEM, 0.5 mM glucose, 0.5 mM carnitine, and 1.0
FBS) and fibroblasts were incubated in the presence (control) or absence (treatment) of etomoxir
(an inhibitor of carnitine palmitoyltransferase that facilitates the transfer of fatty acids from the
cytoplasm across the inner mitochondrial membrane). In contrast, to determine OCR of
exogenous fatty acids provided in media and conjugated to BSA, basic media was exchanged for
substrate-limited media and fibroblasts were incubated in the presence of BSA without fatty
acids (control) or BSA with fatty acids (treatment) in the absence of etomoxir. The SeaHorse
XF24 Extracellular Analyzer was run using an 8 min cyclic protocol command (mix for 3 min,
stand 2 min, and measure for 3 min) (47, 48).

Western blot analysis. The relative amounts of protein were determined using Western
blot analysis as previously described (20). The primary antibodies to detect mature sterol
regulatory element-binding protein-1 (SREBP-1) and sterol regulatory element-binding protein-2
(SREBP-2) protein were purchased from Cayman Chemical (10007663) and Novus Biologicals
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(100-2215), respectively. The primary antibody to detect NPC1 protein was custom produced
and affinity purified (Invitrogen). The primary antibodies to detect phosphorylated hormone
sensitive lipase (pHSL) and hormone sensitive lipase (HSL) were purchased from Cell Signaling
Technology (4139 and 4107). Finally, the antibodies to detect GAPDH and -actin used as
loading controls were purchased from Abcam (ab8245) and Sigma (A5316), respectively.

Statistical analysis. Quantitative data (except growth data analysis) is represented as the
mean  standard error of the mean (SEM) within a group of mice, tissues, or fibroblasts.
Significant differences (P  0.05) were determined using conventional or repeated measures
ANOVA.

Results
Growth data analysis and glucose tolerance test. The Npc1+/+ and Npc1+/- mice fed a
LFD or HFD were used for growth data analysis and glucose tolerance tests to quantitatively
define and verify the Npc1 gene-diet interaction in relation to weight gain and glucose tolerance.
Fitted growth trajectories were derived from our original growth data for Npc1+/+ and Npc1+/mice fed a LFD or HFD from 4 to 20 weeks of age. The Npc1+/+ and Npc1+/- mice fed a LFD had
no significant difference in growth trajectories (Fig. 1A). In contrast, Npc1+/- mice fed a HFD
had a significantly increased growth trajectory compared to Npc1+/+ mice fed the same diet. With
respect to the glucose tolerance test performed at 20 weeks of age, Npc1+/+ and Npc1+/- mice fed
a LFD had no significant difference in glucose tolerance (Fig. 1B). However, Npc1+/+ and
Npc1+/- mice fed a HFD had significantly impaired fasting glucose and glucose tolerance
compared to Npc1+/+ and Npc1+/- mice fed a LFD. There was no significant difference in fasting
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glucose and glucose tolerance for Npc1+/+ and Npc1+/- mice fed a HFD. Therefore, Npc1+/- mice
fed a HFD had a significantly increased growth trajectory but similar impaired fasting glucose
and glucose tolerance compared to Npc1+/+ mice fed the same diet.

Amounts of liver NPC1 protein. A schematic representation is provided for the normal
and truncated (non-functional) NPC1 protein (Fig. 2A). The NPC1 protein antibody recognition
site located near the carboxyl-terminus is absent from the truncated NPC1 protein and therefore
not detected using the NPC1 antibody. The amounts of NPC1 protein in livers from Npc1+/- mice
fed a LFD was significantly decreased (68%) compared to Npc1+/+ mice fed the same diet (Fig.
2B and 2C). Although the amounts of NPC1 protein from Npc1+/- mice fed a HFD was not
significantly different compared to Npc1+/- mice fed a LFD, the amounts of NPC1 protein from
Npc1+/+ mice fed a HFD was significantly increased (89%) compared to Npc1+/+ mice fed a LFD.
Therefore, Npc1+/- mice fed a HFD had significantly decreased and also non-responsive
expression of the Npc1 gene compared to Npc1+/+ mice fed the same diet.

Amounts of liver SREBP protein. The amounts of SREBP-1 protein in livers from Npc1+/mice fed a LFD or HFD was significantly increased (117% and 172%, respectively) compared to
Npc1+/+ mice fed a LFD (Fig. 3A and 3B). Moreover, the amounts of SREBP-1 protein in livers
from Npc1+/+ mice fed a HFD was significantly increased (120%) compared to Npc1+/+ mice fed
a LFD. However, the amounts of SREBP-2 protein in livers from Npc1+/+ and Npc1+/- mice fed a
LFD or HFD was not significantly different (Fig. 3C and 3D). Therefore, although Npc1+/- mice
fed a HFD had similar amounts of mature SREBP-1 and SREBP-2 protein compared to Npc1+/+
mice fed the same diet, Npc1+/- mice fed a LFD or HFD had increased amounts of mature

20

SREBP-1 protein compared to Npc1+/+ mice fed a LFD.

Physical and biochemical analyses. Physical and biochemical analyses was performed on
Npc1+/+ and Npc1+/- mice fed a LFD or HFD at 20 weeks of age. The Npc1+/- mice fed a HFD
had significantly increased body weights (13%) compared to Npc1+/+ mice fed the same diet
(Table 1). The results also indicated that Npc1+/- mice fed a HFD had significantly increased
liver weights (27%) and adipose weights (14%) compared to Npc1+/+ mice fed the same diet.
Moreover, Npc1+/- mice fed a HFD had significantly increased concentrations of liver cholesterol
(24%) and liver triacylglycerol (39%) compared to Npc1+/+ mice fed the same diet. In support of
these results, Npc1+/- mice fed a HFD had increased expression of genes encoding proteins for
the integrated PGC-1, LXR/, and SREBP-1 pathway (but not SREBP-2 pathway), glycolysis
pathway, and lipogenesis pathway compared to Npc1+/+ mice fed the same diet as determined
using RNA microarray analysis (Table 2). With respect to plasma components, Npc1+/- mice fed
a HFD had significantly increased concentrations of cortisol (10%), insulin (82%), and ALT
(59%) compared to Npc1+/+ mice fed the same diet. The increased concentrations of cortisol and
insulin are expected to alter regulation of the glycolysis, lipogenesis, and lipolysis pathways
known to effect energy metabolism. Therefore, Npc1+/- mice fed a HFD had significantly
increased body weights and tissue weights (liver and adipose) in addition to increased expression
of genes (insulin and cortisol) responsible for weight gain compared to Npc1+/+ mice fed the
same diet.

Metabolic phenotype analyses. Metabolic phenotype analyses were performed using a
separate group of Npc1+/+ and Npc1+/- mice fed a LFD until 10 weeks of age and afterwards fed a
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HFD for 9 days at the University of Washington Health Sciences Center. Consistent with results
provided in the previous section at the University of New Mexico Health Sciences Center,
Npc1+/- mice fed a HFD had significantly increased body weights (5.1%) compared to Npc1+/+
mice fed the same diet (Fig. 4A). This increase in body weight was characterized by significantly
increased lean mass (3.4%) and fat mass (11.3%) compared to Npc1+/+ mice fed the same diet
(Fig. 4B and 4C). There was no significant difference in food or water intake for Npc1+/+ and
Npc1+/- mice fed a LFD or HFD during the light and dark cycle (Fig. 4D and 4E). Moreover,
there was no significant difference in volume of oxygen consumption (VO 2) or volume of carbon
dioxide elimination (VCO2) for Npc1+/+ and Npc1+/- mice fed a LFD or HFD during the light or
dark cycle, although Npc1+/+ and Npc1+/- mice fed a LFD or HFD during the dark cycle had
increased VO2 and VCO2 compared to the same mice fed a LFD or HFD during the light cycle as
would be expected for nocturnal animals (Fig. 4F and 4G). Consequently, there was no
significant difference in the respiratory quotient (RQ = VCO 2 elimination/VO2 consumption)
(data not shown). Finally, there was no significant difference in locomotor activity or heat
production for Npc1+/+ and Npc1+/- mice fed a LFD or HFD during the light or dark cycle (Fig.
4H and 4I). Therefore, although Npc1+/- mice fed a HFD had increased body weights compared
to Npc1+/+ mice fed the same diet, metabolic phenotype analysis was unable to detect differences
in these determinants of energy balance.

Intestinal lipid absorption and fecal lipid content. Intestinal lipid absorption and fecal
lipid content was measured to determine whether increased absorption might account for weight
gain. There was no significant difference of intestinal lipid absorption for Npc1+/+ and Npc1+/mice fed a LFD until 10 weeks of age and afterwards fed a HFD-sucrose polybehenate for 3 days
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(Fig. 5A). Moreover, these same mice subsequently fed a HFD for 10 days had no significant
difference in the concentration of total fecal lipid content (Fig. 5B) or fecal lipid composition
(cholesterol, triacylglycerol, and fatty acids) (Fig. 5C). Therefore, Npc1+/- mice fed a HFD had
no significance difference in lipid absorption or fecal lipid content compared to Npc1+/+ mice fed
the same diet.

Adipose lipolysis and amounts of phosphorylated hormone sensitive lipase protein. The
amounts of glycerol released (a measure of triacylglycerol lipolysis and mobilization) from
adipose of Npc1+/- fed a HFD until 10 weeks of age was significantly decreased (19.9%)
compared to adipose of Npc1+/+ mice fed the same diet (Fig. 6A). Moreover, the amounts of
pHSL and pHSL/HSL (relative and adjusted measure of activated HSL protein) from adipose of
Npc1+/- mice fed a HFD was significantly decreased (52.1% and 50.4%, respectively) compared
to adipose of Npc1+/+ mice fed the same diet (Fig. 6B and 6C). Therefore, Npc1+/- mice fed a
HFD had decreased activation of HSL, decreased triacylglycerol lipolysis, and decreased
glycerol mobilization compared to Npc1+/+ mice fed the same diet.

Fibroblast glycolytic metabolism and oxidative metabolism. A measure of basal
glycolytic metabolism (extracellular acidification rate or ECAR) for Npc1+/- fibroblasts grown
and assayed in basic media was significantly increased (31%) compared to Npc1+/+ fibroblasts
grown and assayed in the same media (Fig. 7A). However, a measure of basal oxidative
metabolism (oxygen consumption rate or OCR) for Npc1+/- fibroblasts grown and assayed in
basic media was significantly decreased (46%) compared to Npc1+/+ fibroblasts grown and
assayed in the same media (Fig. 7B). In addition, a measure of basal endogenous fatty acid
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oxidative metabolism stored in the form of triacylglycerol for Npc1+/- fibroblasts grown in basic
media and assayed in substrate-limited media was significantly decreased (93%) compared to
Npc1+/+ fibroblasts grown and assayed in the same media (Fig. 7C). In direct contrast, a measure
of basal exogenous fatty acid oxidative metabolism provided in the form of BSA and conjugated
fatty acids for Npc1+/- fibroblasts grown in basic media and assayed in substrate-limited media
was significantly increased (1174%) compared to Npc1+/+ fibroblasts grown and assayed in the
same media (Fig. 7D). Therefore, Npc1+/- fibroblasts had increased basal glycolysis but
decreased endogenous and total fatty acid oxidation metabolism compared to Npc1+/+
fibroblasts.

Cellular growth curves, mitochondrial content, and metabolic adaptations. Cellular
growth curves for Npc1+/- fibroblasts grown in basic media was significantly decreased (27%) as
measured using cell confluence during 96 hours compared to Npc1+/+ fibroblasts grown in the
same media (Fig. 8A). Mitochondrial content and concentration of ATP for Npc1+/- fibroblasts
grown in basic media was significantly decreased (32% and 53%, respectively) at 96 h compared
to Npc1+/+ fibroblasts grown in the same media (Fig. 8B and 8C). Finally, amounts of
triacylglycerol and cholesterol for Npc1+/- fibroblasts grown in basic media was significantly
increased (44% and 31%, respectively) at 96 h compared to Npc1+/+ fibroblasts grown in the
same media (Fig. 8D, 8E, and 8F). Therefore, Npc1+/- fibroblasts were characterized by a slower
growth rate, decreased mitochondria, and decreased ATP production but increased neutral lipid
storage compared to Npc1+/+ fibroblasts.

Discussion
The objective for this study was to determine the physiological basis for the Npc1 gene24

diet interaction that promotes weight gain. This study was initiated by performing statistical
analysis of our original growth data to model fitted growth trajectories and therefore characterize
the Npc1 gene-diet interaction responsible for weight gain. A series of in vivo and in vitro studies
were performed to measure differences in body composition, food and water intake, determinants
of energy expenditure (oxygen consumption, carbon dioxide elimination, locomotor activity, and
heat production), intestinal fat absorption, liver lipogenesis, adipose lipolysis, and fibroblast
energy metabolism. Together, the combined results determined that the Npc1 gene-diet
interaction does not influence weight gain through food intake, determinants of energy
expenditure, or intestinal fat absorption, but instead through altered energy metabolism involving
liver lipogenesis and adipose lipolysis.
A key finding of our in vivo studies was that Npc1+/- mice fed a LFD or HFD have
increased liver triacylglycerol (hepatic steatosis) compared to Npc1+/+ mice fed the same diet at
20 weeks of age, consistent with our previous study showing that Npc1+/- mice fed a LFD
develop hepatic steatosis at 5 weeks in the absence of weight gain (12). These studies also
indicated that Npc1+/- mice have impaired feedback inhibition (activation) of the liver SREBP-1
pathway, whereby increased amounts of SREBP-1 protein is known to serve as a potent
transcription factor for increasing hepatic glycolysis and lipogenesis (14). The physical
phenotype resulting from impaired feedback inhibition of the SREBP-1 pathway has previously
been characterized using mice that overexpress the Srebp-1 gene and human SREBP-1 gene
gain-of-function variants reported to be associated with hepatic steatosis and weight gain (2, 8).
Therefore, our results indicating that Npc1+/- mice fed a HFD have impaired feedback inhibition
of the SREBP-1 pathway and increased expression of target genes encoding for proteins
participating in glycolysis and lipogenesis is proposed to represent the “liver component” for the
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Npc1 gene-diet interaction responsible for weight gain. Similarly, our results indicating that
Npc1+/- mice fed a HFD have decreased phosphorylation (inactivation) of adipose HSL protein
that catalyzes hydrolysis of adipose triacylglycerol and mobilization of fatty acids is proposed to
represent the “adipose component” of the Npc1 gene-diet interaction responsible for weight gain.
These tissue specific metabolic abnormalities, in combination with Npc1+/- mice fed a HFD
having increased expression of the PGC-1 transcription coactivator, are fully supported by
studies demonstrating that a HFD increases expression of the PGC-1 transcriptional coactivator
to potentiate LXR nuclear receptor transcriptional activity and hence Srebp-1 gene expression to
differentially regulate tissue lipogenesis and lipolysis (16, 27, 34, 35). Moreover, the Npc1+/mice fed a HFD were found to have significantly increased concentrations of plasma cortisol and
insulin known to increase both liver and adipose lipogenesis, while at the same time inhibiting
adipose lipolysis in the presence of insulin resistance (7, 38).
The increased liver lipogenesis and decreased adipose lipolysis was phenotypically
consistent with our in vitro studies performed using Npc1+/+ and Npc1+/- fibroblasts indicating
altered cellular energy metabolism of glucose and fatty acids as evidenced by an accumulation of
neutral lipid (cholesterol and triacylglycerol). More specifically, these studies indicated that
Npc1+/- fibroblasts have increased basal glycolytic metabolism but decreased basal oxidative
metabolism compared to Npc1+/+ fibroblasts grown in the same media. Moreover, the Npc1+/fibroblasts also have decreased basal oxidative metabolism of endogenous fatty acids but
increased basal oxidative metabolism of exogenous fatty acids compared to Npc1+/+ fibroblasts
grown in the same media. The decreased oxidative metabolism of glucose could be attributed to
the decreased mitochondrial content and/or function, thereby diverting glucose substrate into the
synthesis of neutral lipids as evidenced by an accumulation of cholesterol and triacylglycerol.

26

This particular result is consistent with another study indicating that NPC1 deficiency leads to
alterations in mitochondrial function and energy metabolism, including increased glycolysis and
oxidative metabolism (25). Moreover, the decreased oxidative metabolism of endogenous fatty
acid in the form of triacylglycerol suggests a deficiency in triacylglycerol lipolysis, particularly
since oxidative metabolism of exogenous fatty acid is capable of compensating for this
deficiency as evidenced by increased oxidative metabolism to increase cellular energy balance.
A schematic representation of the proposed physiological basis for the Npc1 gene-diet interaction
that promotes weight gain is provided (Fig. 9). And finally, a recent study has reported that rare
NPC1 gene loss-of-function mutations among male NPC1 heterozygotes fed a HFD have a
significantly higher BMI of high penetrance compared to matched controls or whole populationbased controls, thereby validating our present studies indicating an Npc1 gene-diet interaction
(28).
In summary, the present study has shown that Npc1+/- mice with decreased gene dosage
interacts with a HFD to promote positive energy balance and weight gain compared to Npc1+/+
mice fed the same diet. The physiological basis for the Npc1 gene-diet interaction indicates that
impaired feedback inhibition of the SREBP-1 pathway increases liver glycolysis and lipogenesis,
in addition to decreases in adipose lipolysis thereby resulting in an accumulation of neutral lipids
in both tissues. These mouse tissue specific abnormalities were consistent with in vitro studies
using Npc1+/+ and Npc1+/- mouse fibroblasts indicating an increased flux of glucose substrate
through the lipogenesis pathway to enhance storage of neutral lipids in combination with
deficient lipolysis and oxidative metabolism of endogenous fatty acids in the form of
triacylglycerol. Together, this study provides novel insight into the physiological basis for how
the Npc1 gene in mice, and indirectly the NPC1 gene in humans, is involved in maintaining
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cellular, tissue, and whole body energy balance.
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Figures

Figure 1. Growth data analysis and glucose tolerance test. A: Growth data analysis using fitted
growth trajectories for Npc1+/+ and Npc1+/- mice fed a LFD or HFD from 4 to 20 weeks. The
model estimation takes into account sources of variability in the estimation of model parameters
but elected not to illustrate this variability with 95% confidence intervals since it would detract
from the interpretation. B: Glucose tolerance test for Npc1+/+ and Npc1+/- mice fed a LFD or
HFD at 20 weeks. Values are means  SEM of 14-15 mice per group. *P  0.05 compared to
Npc1+/+ mice fed a LFD. **P  0.05 compared to Npc1+/+ mice fed a HFD. LFD, low-fat diet;
HFD, high-fat diet.
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Figure 2. Amounts of liver NPC1 protein. A: Schematic representation of the normal and
truncated NPC1 protein. A retroposon insertion terminates protein translation producing a
truncated NPC1 protein (non-functional) responsible for the null mutation. The transmembrane
domains are indicated by vertical bars and the NPC1 protein antibody recognition site is
indicated by an arrow near the carboxyl terminus. B: Representative Western blot analysis of
liver NPC1 protein and -actin for Npc1+/+ and Npc1+/- mice fed a LFD or HFD at 20 weeks C:
Amounts of liver NPC1 protein adjusted for -actin and normalized to amounts of liver NPC1
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protein for Npc1+/+ mice fed a LFD. Values are means  SEM of 6 mice per group. *P  0.05
compared to Npc1+/+ mice fed the same diet. **P  0.05 compared to Npc1+/+ mice fed a LFD.
LFD, low-fat diet; HFD, high-fat diet.
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Figure 3. Amounts of liver SREBP protein. A: Representative Western blot analysis of liver
SREBP-1 protein and -actin for Npc1+/+ and Npc1+/- mice fed a LFD or HFD at 20 weeks. B:
Amounts of liver SREBP-1 protein adjusted for -actin and normalized to amounts of liver
SREBP-1 protein for Npc1+/+ mice fed a LFD. C: Representative Western blot analysis of liver
SREBP-2 protein and -actin for Npc1+/+ and Npc1+/- mice fed a LFD or HFD at 20 weeks. D:
Amounts of liver SREBP-2 protein adjusted for -actin and normalized to amounts of SREBP-2
protein for Npc1+/+ mice fed a LFD. Values are means  SEM of 6 mice per group. *P  0.05
compared to Npc1+/+ mice fed a LFD. LFD, low-fat diet; HFD, high-fat diet; SREBP, sterol
regulatory element-binding protein.
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Figure 4. Metabolic phenotype analyses. A: Change in body weights for Npc1+/+ and Npc1+/mice fed a LFD at 10 weeks and after fed a HFD for 9 days. B: Change in lean mass for Npc1+/+
and Npc1+/- mice fed a LFD at 10 weeks and after fed a HFD for 9 days. C: Change in fat mass
for Npc1+/+ and Npc1+/- mice fed a LFD at 10 weeks and after fed a HFD for 9 days. D: Change
in food intake for Npc1+/+ and Npc1+/- mice fed a LFD at 10 weeks and after fed a HFD for 9
days during the light and dark cycle. E: Change in water intake for Npc1+/+ and Npc1+/- mice fed
a LFD at 10 weeks and after fed a HFD for 9 days during the light and dark cycle. F: Change in
oxygen consumption for Npc1+/+ and Npc1+/- mice fed a LFD at 10 weeks and after fed a HFD
for 9 days during the light and dark cycle. G: Change in carbon dioxide elimination for Npc1+/+
and Npc1+/- mice fed a LFD at 10 weeks and after fed a HFD for 9 days during the light and dark
cycle. H: Change in locomotor activity for Npc1+/+ and Npc1+/- mice fed a LFD at 10 weeks and
after fed a HFD for 9 days during light and dark cycle. I: Change in heat production for Npc1+/+
and Npc1+/- mice fed a LFD at 10 weeks and after fed a HFD for 9 days during the light and dark
cycle. Values are means  SEM of 9-10 mice per group. *P  0.05 compared to Npc1+/+ mice fed
the same diet. LFD, low-fat diet; HFD, high-fat diet; VO 2, volume of oxygen consumption;
VCO2, volume of carbon dioxide elimination.
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Figure 5. Intestinal lipid absorption and fecal lipid content. A: Intestinal lipid absorption for
Npc1+/+ and Npc1+/- mice fed a LFD at 10 weeks of age and afterwards fed a HFD-sucrose
polybehenate for 3 days. B: Total lipid in fecal pellets for Npc1+/+ and Npc1+/- mice after fed a
HFD for 10 days. C: Lipid composition of fecal pellets for Npc1+/+ and Npc1+/- mice after fed a
HFD for 10 days. Values are means  SEM of 8-10 mice per group. *P  0.05 compared to
Npc1+/+ mice fed the same diet. LFD, low-fat diet; HFD, high-fat diet; HFD-SPB, high-fat diet
containing sucrose polybehenate; TC, total cholesterol; TG, triacylglycerol; FA, fatty acids.
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Figure 6. Adipose lipolysis and amounts of phosphorylated hormone sensitive lipase protein. A:
Glycerol release (concentration of glycerol released into media) from adipose lipolysis for
Npc1+/+ and Npc1+/- mice fed a HFD at 10 weeks. B: Representative Western blot analysis of
adipose pHSL, HSL, and GAPDH protein for Npc1+/+ and Npc1+/- mice fed a HFD at 10 weeks.
C: Amounts of adipose pHSL, HSL, and pHSL/HSL protein adjusted for GAPDH and
normalized to the amounts of adipose pHSL, HSL, and pHSL/HSL protein for Npc1+/+ fed a
HFD at 10 weeks. Values are means  SEM of 8-10 mice per group for glycerol release and 5
mice per group for Western blot analysis. *P  0.05 compared to Npc1+/+ mice fed the same diet.
LFD, low-fat diet; HFD, high-fat diet; HSL, hormone sensitive lipase; pHSL, phosphorylated
HSL; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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Figure 7. Fibroblast glycolytic metabolism and substrate oxidative metabolism. A: Basal
glycolytic metabolism for Npc1+/+ and Npc1+/- fibroblasts grown and assayed in basic media. B:
Basal glucose oxidative metabolism for Npc1+/+ and Npc1+/- fibroblasts grown and assayed in
basic media. C: Basal endogenous fatty acid oxidative metabolism for Npc1+/+ and Npc1+/fibroblasts grown in basic media and assayed in substrate-limited media. D: Basal exogenous
fatty acid oxidative metabolism for Npc1+/+ and Npc1+/- fibroblasts grown in basic media and
assayed in substrate-limited media. Values are means  SEM of 15 wells for Npc1+/+ and Npc1+/fibroblasts. *P  0.05 compared to Npc1+/+ fibroblasts grown and assayed in the same media.
ECAR, extracellular acidification rate; OCR, oxygen consumption rate.
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Figure 8. Cellular growth curves, mitochondrial content, and metabolic adaptations. A: Cellular
growth curves for Npc1+/+ and Npc1+/- fibroblasts grown and assayed in basic media during 96 h.
B: Mitochondrial content for Npc1+/+ and Npc1+/- fibroblasts grown and assayed in basic media
at 96 h. C: Concentration of ATP for Npc1+/+ and Npc1+/- fibroblasts grown and assayed in basic
media at 96 h. D: Representative images of triacylglycerol staining for Npc1+/+ and Npc1+/fibroblasts grown and assayed in basic media at 96 h. E: Amounts of triacylglycerol for Npc1+/+
and Npc1+/- fibroblasts grown and assayed in basic media at 96 h. F: Amounts of cholesterol for
Npc1+/+ and Npc1+/- fibroblasts grown and assayed in basic media at 96 h. Values are means 
SEM of 15 wells for Npc1+/+ and Npc1+/- fibroblasts. *P  0.05 compared to Npc1+/+ fibroblasts
grown and assayed in the same media.
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Figure 9. Schematic representation of the proposed physiological basis for the Npc1 gene-diet
interaction that promotes weight gain. The NPC1 gene and modifying gene interactions proposed
to represent a causal metabolic pathway that predisposes to obesity or diabetes depending on
race/ethnicity. A. Dietary saturated fatty acids increase expression of the PGC-1 and PGC1-
genes and amounts of encoded PGC-1 and PGC1- proteins. B. The PGC-1 and PGC1-
proteins serve as transcriptional coactivators for the nuclear receptor LXR (activated by
oxysterol) that forms a heterodimer with RXR (activated by retinoic acid) to increase expression
of the SREBP-1 gene and amount of encoded precursor SREBP-1 protein. C. NPC1 gene risk
variants (human) or decreased NPC1 gene dosage (mouse) decreases encoded NPC1 protein
function to impair feedback inhibition of the SREBP pathway marked by an increased amount of
mature SREBP-1 protein that serves as a transcription factor. D. The increased amount of PGC1 protein (but not PGC-1) serves as a transcriptional coactivator for the increased amount of
mature SREBP-1 protein to increase expression of target genes encoding proteins that regulate
glycolysis and lipogenesis but also decrease expression of the PPAR gene and amount of
encoded PPAR protein. E. The decreased amount of PPAR protein that forms a heterodimer
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with RXR decreases expression of target genes. F. These target genes encode proteins that
regulate lipolysis and fatty acid catabolism (-oxidation). Therefore, the NPC1 gene-diet
interaction is responsible for promoting positive energy balance through increased glycolysis and
lipogenesis in addition to decreased lipolysis and fatty acid -oxidation. PGC-1, peroxisomeproliferator activated receptor gamma coactivator-1 alpha; PGC-1 peroxisome-proliferator
activated receptor gamma coactivator-1 beta; LXR, liver X receptor; RXR, retinoid X receptor;
LXRE, liver X receptor response element; SREBP-1, sterol regulatory element-binding protein1; SRE, sterol regulatory element-binding protein response element; PPAR, peroxisomeproliferator activated receptor alpha; PPRE, peroxisome-proliferator activated receptor response
element.
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Table 1. Physical and biochemical measures for Npc1+/+ and Npc1+/- mice fed a LFD or HFD
+/+ LFD
+/- LFD
+/+ HFD
+/- HFD
Physical Measures
Body weights, g
Liver weights, g
Adipose weights, g

32.5 ± 0.5
1.48 ± 0.04
0.57 ± 0.05

30.8 ± 0.8
1.44 ± 0.04
0.49 ± 0.04

34.8 ± 0.8
1.64 ± 0.05
1.11 ± 0.06

39.2 ± 0.9*
2.08 ± 0.07*
1.26 ± 0.04*

Liver Concentrations
C, nmol/mg protein
CE, nmol/mg protein
FFA, nmol/mg protein
TAG, nmol/mg protein

7.64 ± 0.52
4.88 ± 0.44
5.43 ± 1.71
260 ± 10

7.08 ± 0.25
5.10 ± 1.07
7.29 ± 1.40
363 ± 70*

7.25 ± 0.34
8.94 ± 1.46
14.7 ± 0.7
618 ± 36

8.96 ± 0.18*
8.56 ± 0.55
15.9 ± 1.2
858 ± 38*

Plasma Concentrations
TAG, mmol/L
TC, mmol/L
Cortisol, ng/L
Insulin, mg/L
IL-1β, ng/L
IL-6, ng/L
TNF-α, ng/L
AST, U/L
ALT, U/L

1.51 ± 0.12
4.04 ± 0.30
4.47 ± 0.19
1.43 ± 0.13
26.4 ± 2.1
34.1 ± 8.4
28.5 ± 5.1
152 ± 32
79 ± 23

1.19 ± 0.16
4.13 ± 0.22
4.50 ± 0.19
1.09 ± 0.10
25.8 ± 1.5
35.5 ± 8.9
47.4 ± 8.9
168 ± 12
97 ± 17

1.18 ± 0.07
4.56 ± 0.16
5.2 ± 0.18
1.48 ± 0.18
26.2 ± 1.7
36.9 ± 4.6
21.4 ± 2.0
138 ± 25
162 ± 30

1.06 ± 0.09
4.12 ± 0.22
5.72 ± 0.18*
2.70 ± 0.30*
23.3 ± 2.5
36.7 ± 2.6
23.2 ± 4.0
171 ± 22
258 ± 22*

Values are means  SEM for 14-15 mice per group at 30 weeks. * P  0.05 compared to Npc1+/+
mice fed a HFD. ALT, alanine aminotransferase; AST, aspartate aminotransferase; C,
cholesterol; CE, cholesterol ester; FFA, free fatty acid; TC, total cholesterol; TAG,
triacylglycerol. LFD, low-fat diet; HFD, high-fat diet.
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Table 2. RNA microarray of livers from Npc1+/+ and Npc1+/- mice fed a HFD
Gene Product
Abbreviation

Fold 

Sterol regulatory element-binding protein pathway
Peroxisome proliferator-activated receptor  coactivator 1-
Peroxisome proliferator-activated receptor  coactivator 1-
Liver X receptor 
Liver X receptor 
Retinoid X receptor 
Insulin induced gene 1
Insulin induced gene 2
Sterol regulatory element-binding protein cleavage activating
protein
Sterol regulatory element-binding protein-1
Sterol regulatory element-binding protein-2

Pgc1a
Pgc1b
Lxra
Lxrb
Rxra
Insig1
Insig2
Scap

1.38*
0.93
1.25*
1.18
1.28
1.13
0.75
1.13

Srebp1
Srebp2

1.98*
1.00

Peroxisome proliferator-activated receptor pathway
Peroxisome proliferator-activated receptor α
Peroxisome proliferator-activated receptor δ
Peroxisome proliferator-activated receptor γ

Ppara
Ppard
Pparg

0.58*
1.00
0.89

Glycolysis pathway
Glucose kinase
Glucose kinase regulatory protein
Phosphoglucomutase
Phosphofructokinase
Aldolase
Triose phosphate mutase
Glyceraldehyde 3-phosphate dehydrogenase
Phosphoglycerate kinase
Phosphoglycerate isomerase
Enolase
Pyruvate kinase

Gck
Gckr
Pgm
Pfk
Aldo
Tpm
Gapdh
Pgk
Pgam
Enoa
Pklr

2.21*
1.30*
0.93
1.23
1.10
1.04
1.06
1.00
1.00
1.00
1.39*

Pdh
Cs
Aco
Idh
kgdh
Scs
Sdha

1.46*
1.25*
1.14
0.98
1.00
1.00
1.05

Tricarboxylic acid cycle pathway
Pyruvate dehydrogenase
Citrate synthase
Aconitase
Isocitrate dehydrogenase
Ketoglutarate dehydrogenase
Succinyl-CoA synthetase
Succinate dehydrogenase
42

Fumarate dehydratase
Malate dehydrogenase
Lipogenesis pathway
ATP citrate lyase
Acetyl-CoA carboxylase
Fatty acid synthase
Steroyl-CoA desaturase
3-hydroxy-3-methylglutaryl-CoA synthase
3-hydroxy-3-methylglutaryl-CoA reductase
Malic enzyme
Glucose 6-phosphate dehydrogenase
Phosphogluconate dehydrogenase

Fd
Mdh

1.06
1.00

Acly
Acac
Fasn
Scd
Hmgcs
Hmgcr
Mod
G6pdh
Pgd

0.96
1.28*
1.80*
1.51*
1.00
1.59
1.16
1.00
1.25*

Values represent the fold change (increased or decreased) of mRNA levels for Npc1+/- mice
compared to Npc1+/+ fed a HFD. An asterisk indicates at least a 1.25-fold increase or decrease
in amounts of mRNA (mean value of 3 mice per group). The fold change for genes indicated by
an asterisk represent those genes previously reported to be upregulated or downregulated as a
result of activation by the SREBP-1 pathway (29).
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Abstract
Niemann-Pick C1 (NPC1) is a late endosomal / lysosomal membrane-spanning protein
that is responsible for lipid trafficking. The NPC1 gene has been associated with obesity and
diabetes in genome wide association studies and follow up meta-analyses. To characterize the
mechanism for NPC1’s role in predisposition to obesity, we developed a BALBc mouse model
with 50% NPC1 gene dosage. With this mouse model we have demonstrated a gene-diet
interaction between NPC1 gene dosage and a high-fat diet. Using this mouse model, we were
able to identify a metabolic pathway that connects decreased NPC1 function with a high fat diet.
We have termed this pathway ‘the NPC1 pathway.’
A local cohort of 357 individuals consented to give blood for DNA extraction and to have
their de-identified clinical information compared to their genotypes for certain gene variants.
Individuals were from either an outpatient clinic in Albuquerque, NM or were patients or
volunteers from the University of New Mexico Hospital. Volunteers were given a questionnaire
to self-report their race and ethnicity. Information was then blinded before being provided to
researchers. In this study, we perform multiple multinomial logistic regression analysis to
determine if gene variants along the NPC1 Pathway are interacting to contribute to clinical
endpoints of obesity (BMI) and diabetes (elevated hemoglobin A1C).
We hypothesize that this analysis of genotypic and clinical patient data will provide sufficient
evidence to support the existence of the NPC1 pathway in humans.
To confirm this pathway’s existence in humans, we have carried out this translational
study in the hopes of finding interactions between gene variants within the proposed pathway.
Although gene variant associations with clinical endpoints such as BMI have been reported,
interactions between these gene variants have not. We hypothesized that gene variant
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interactions along this pathway would show previously undescribed correlations with clinical
phenotypes. The goal is to better understand how gene variants interact to modify individual
metabolism pathways. With this information we may better equip healthcare professionals with
genotype-based lifestyle therapies and intervention.

Introduction
The human Niemann-Pick C1 (NPC1) gene has been found to be associated with obesity
and type 2 diabetes mellitus in population-based studies. For instance, the first genome-wide
association studies (GWAS) performed to identify obesity susceptibility genes revealed that
common NPC1 gene ancestral risk alleles (644A>G encoding His215Arg and 2572A>G encoding
Ile858Val) in linkage-disequilibrium were associated with morbid-adult obesity in a European
population (1). A number of subsequent studies confirmed these results and also implicated a third
common NPC1 gene ancestral risk allele (1926G>C encoding Met642Ile) that in linkagedisequilibrium with the other risk alleles and associated with obesity or type 2 diabetes (2-5). More
recently, a study has indicated that 17 rare NPC1 gene derived risk alleles (minor allele frequency
<1%) are associated with a high penetrance of obesity (6).
At the same time we had reported a series of articles indicating that different NPC1 mouse
strains characterized with decreased gene dosage and thus expressing decreased amounts of
encoded NPC1 protein was predisposed to excessive weight gain when fed a high-fat diet (but not
when fed a low-fat diet) thereby consistent with an NPC1 gene x diet interaction that involved
nutrient-sensing modifying genes (7-10). Soon thereafter, one of these first mouse GWAS that
used 100 inbred strains indicated that the NPC1 mouse model fed a high-fat and high sucrose diet
represented one of eleven genes strongly associated with body fat percentage (11).
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To characterize the undefined NPC1 gene x diet interaction and identify the nutrientsensing modifying genes responsible for obesity and type 2 diabetes using the NPC1 mouse model,
we performed a comprehensive genomic, biochemical, and physiological study that indicated
differential regulation of central energy metabolism pathways (increased energy storage pathways
such as glycolysis and lipogenesis and decreased energy release pathways such as lipogenesis and
-oxidation) for these phenotypes (12). In brief, although there was no significant difference
between NPC1+/+ and NPC1+/- mice fed a high-fat diet with respect to i) food and water intake, ii)
oxygen consumption, iii) carbon dioxide elimination, iv) locomotor activity, v) adaptive
thermogenesis, and vi) intestinal lipid absorption, the livers of NPC1 +/- mice had significantly
increased amounts of mature sterol regulatory element-binding protein-1c (SREBP1c) protein that
resulted in increased expression of SREBP1c target genes that upregulated the glycolysis and
lipogenesis metabolic pathways with an accumulation of triacylglycerol and cholesterol.
Moreover, the adipose of NPC1+/- mice had significantly decreased amounts of phosphorylated
and activated hormone-sensitive lipase (p-HSL) that resulted in decreased adipose triacylglycerol
lipolysis, mobilization of fatty acids, and -oxidation. Consistent with these results performed
using mouse liver and adipose tissue, cellular energy metabolism studies indicated that NPC1 +/mouse fibroblasts had significantly increased basal glycolysis and lipogenesis and significantly
decreased basal substrate (glucose and endogenous fatty acid) oxidation with an accumulation of
triacylglycerol and cholesterol. These combined results using both mouse tissues (in vivo) and
fibroblasts (ex vitro) allowed us to propose the “NPC1 gene x nutrient metabolic pathway”
composed of four nutrient-sensing modifying genes with established roles in differential regulation
of central energy metabolism pathways (Fig. 1).
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The objective for our present study was to validate the proposed NPC1 gene x nutrient
metabolic pathway using a phenotypically defined metabolic disease case-control cohort
consisting of 357 participants. To perform this study we identified and used the metabolic disease
associated single nucleotide polymorphisms (SNPs) of the NPC1 gene and several nutrient-sensing
modifying genes (caveolin-1 gene or CAV1, liver X receptor alpha gene or LXR, liver X receptor
beta or LXR, peroxisome proliferator-activated receptor gamma coactivator 1 beta gene or
PGC1, and sterol regulatory element-binding protein 1c gene or SREBP1c) to first test
association with BMI and HbA1c categories using simple multinomial logistic regression and
second to interaction and association with BMI and HbA1c categories using multiple multinomial
logistic regression. In summary, the results indicated that the NPC1 gene risk alleles interacted
with different nutrient-sensing modifying gene risk alleles and significantly associated with BMI
and HbA1c categories when stratified by ethnicity.

Research design and methods
Participant cohort
The participant cohort consisted of 357 individuals recruited for a phenotypically defined
metabolic disease case-control study through the Clinical and Translational Sciences Center
(CTSC) at the University of New Mexico Health Sciences Center (UNM HSC). A blood sample
was obtained from individuals to perform multiple loci genotype analysis and determine statistical
association with physical (body mass index or BMI) and metabolic (hemoglobin A1c or HbA1c)
phenotypes. These individuals also self-identified as belonging to an ethnic group, including nonHispanic White (44.8%), Hispanic (40.1%), Native American (6.2%), Asian American (2.8%),
African American (3.1%), or other ethnic group (3.1%). Since the number of individuals from the
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latter four ethnic groups was relatively small and did not provide enough individuals for sufficient
statistical analysis, only the non-Hispanic White (White cohort) and Hispanic (Hispanic cohort)
ethnic groups were used for this study.

Multiple loci genotype analysis
Whole blood samples were obtained from individuals to isolate white blood cells and
extract DNA for multiple loci genotype analysis. The TaqMan SNP allelic discrimination
genotyping assay (Thermo Fisher) was performed for loci in the NPC1 gene and several nutrientregulated modifying genes previously identified using both NPC1 mouse models and NPC1 human
fibroblasts to define gene x gene interactions (epistasis) that occurs within the NPC1 gene
metabolic pathway (12-16). These loci consist of 10 single nucleotide polymorphisms (SNPs) that
have been reported to be associated with metabolic disease phenotypes (obesity and/or type 2
diabetes) and include the following: 3 NPC1 gene SNPs (rs1805081, rs1788799, and rs1805082)
in strong linkage-disequilibrium (D’  0.9), 2 CAV1 gene SNPs (rs926198 and rs3807989) in
strong linkage-disequilibrium (D’  0.9), a LXRα gene SNP (rs2695121), a LXRβ gene SNP
(rs35463555), a PGC1β gene SNP (rs11746690), and 2 SREBP1c gene SNPs (rs2297508,
rs11868035) in moderate linkage-disequilibrium (D’ = 0.6-0.8). The tabulation of pertinent genetic
and molecular information (alleles, position and type, and functional affect) for the NPC1 gene,
CAV1 gene, and modifying genes are provided (Table 1).

Risk alleles and protein function
The 3 NPC1 gene risk alleles have been predicted as benign or neutral (no adverse effect
on gene expression or protein function) according to in silico analysis using the SIFT and
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Polyphen-2 computational methods. However, the 3 common NPC1 gene risk alleles known to be
in linkage-disequilibrium are suspected to be deleterious (adverse effect on gene expression or
protein function) based on published studies indicating that rare loss-of-function alleles are
associated with human obesity and that NPC1 mouse models with decreased gene dosage and
protein function develop obesity and type 2 diabetes (6-8). With respect to the nutrient-regulated
modifying gene risk alleles, both in silico analysis using the SIFT and Polyphen-2 computational
methods and other analyses have indicated these risk alleles are deleterious (adverse effect on gene
expression or protein function) and thus categorized as being either a gain-of-function (G) or lossof-function (L) allele (17-23).

Statistical analysis
The NPC1 gene and modifying gene SNPs were first tested for association with established
BMI and HbA1c categories using simple multinomial logistic regression to confirm previous
GWAS and transferability studies. The NPC1 gene and modifying gene SNPs were second tested
for association with BMI and HbA1c categories using multiple multinomial logistic regressions to
determine interaction that increased or decreased association with BMI and HbA1c categories.
These statistic models were stratified by based on ethnicity (White cohort and Hispanic cohort) to
partially control for genetic background present in these ethnic groups. All P-values were adjusted
using Bonferroni correction. Odds ratios reported from simple multinomial logistic regression
imply an increased risk for the BMI or HbA1C category when the number of risk allele copies
increases by 1. Odds ratios reported from multiple multinomial logistic regressions imply an
increased risk for the BMI or HbA1C category when the number of risk allele copies increases by
1 and the individual has 2 copies of the second risk allele.
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Results
Percentage of individuals in BMI categories compared between the White and Hispanic cohorts
The percentage of individuals in BMI categories were determined and compared between
the White and Hispanic cohorts (Fig. 1A). There was no significant difference in the percentage
of individuals with a normal BMI (20.0-24.9 kg/m2) compared between the White (28.7%) and
Hispanic (24.5%) cohorts. However, the percentage of individuals with an overweight BMI (25.029.9 kg/m2) was significantly increased in the White (29.4%) compared to Hispanic (21.7%)
cohort, while in contrast the percentage of individuals with an obesity BMI (30.0%) was
significantly increased in the Hispanic (53.8%) compared to White (41.9%) cohort. Therefore,
although the percentage of individuals with an overweight BMI (25.0-29.9 kg/m 2) was
significantly increased in the White cohort, the percentage of individuals with an obesity BMI
(30.0%) was significantly increased in the Hispanic cohort.

Percentage of individuals in HbA1c categories compared between the White and Hispanic cohorts
The percentage of individuals in HbA1c categories were determined and compared
between the White and Hispanic cohorts (Fig. 1B). There was no significant difference in the
percentage of individuals with a normal HbA1c (<5.7%) compared between the White (37.4%)
and Hispanic (37.1%) cohorts. However, the percentage of individuals with a prediabetes HbA1c
(5.7-6.5%) was significantly increased in the White (50.7%) compared to Hispanic (40.9%) cohort,
while in contrast the percentage of individuals with a diabetes HbA1c (>6.5%) was significantly
increased in the Hispanic (21.8%) compared to White (11.9%) cohort. Therefore, although the
percentage of individuals with prediabetes HbA1c (5.7-6.5%) was significantly increased in the
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White cohort, the percentage of individuals with diabetes HbA1c (6.5%) was significantly
increased in the Hispanic cohort.

Percentage of individuals with NPC1 gene and modifying gene risk alleles compared between the
White and Hispanic cohorts
The percentage of individuals with NPC1 gene and CAV1 gene risk alleles were determined and
compared between the White and Hispanic cohorts (Fig. 2A). There was no significant difference
in the percentage of individuals with the NPC1 gene ancestral genic risk allele positioned at
nucleotide 644 (A/G) compared between the White (64.7%) and Hispanic (67.5%) cohorts.
However, the percentage of individuals with the NPC1 gene ancestral genic risk allele positioned
at nucleotide 1926 (G/C) was significantly increased in the Hispanic (73.4%) compared to White
(62.2%) cohort, while the third NPC1 gene ancestral genic risk allele positioned at nucleotide 2572
(A/G) was significantly increased in the White (59.4%) compared to Hispanic (39.5%) cohort.
Moreover, with respect to the CAV1 gene derived intron risk alleles (T/C and G/A), there was no
significant difference in the percentage of individuals compared between the White (30.0% and
35.5%) and Hispanic (35.3% and 39.9%) cohorts, respectively. Therefore, the percentage of
individuals with the NPC1 gene ancestral genic risk alleles positioned at nucleotide 1926 (G/C)
and nucleotide 2572 (A/G) were significantly and differentially increased among the Hispanic and
White cohorts. Next, the percentage of individuals with LXR, LXR, PGC1, and SREBP1c
gene risk alleles were determined and compared between the White and Hispanic cohorts (Fig.
2B). There was no significant difference in the percentage of individuals with the LXR gene
derived 5’ untranslated region (5’ UTR) risk allele (C/T) compared between the White (46.2%)
and Hispanic (37.4%) cohorts, while the LXR gene ancestral intron risk allele (G/A) was
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significantly increased in the White (66.3%) compared to Hispanic (52.1%) cohort. There was also
no significant difference in the percentage of individuals with the PGC1 gene derived intron risk
allele (G/A) compared between the White (6.3%) and Hispanic (3.8%) cohorts. However, the
percentage of individuals with the SREBP1c gene ancestral 3’ UTR risk allele (G/C) was
significantly increased in the White (62.3%) compared to Hispanic (48.6%) cohort, while the
SREBP1c gene ancestral splice region risk allele (C/T) was significantly increased in the Hispanic
(45.5%) compared to White (32.5%) cohort. Therefore, the percentage of individuals with the
LXR gene ancestral intron risk allele (G/A), the SREBP1c gene ancestral 3’ UTR risk allele
(G/C), and the SREBP1c gene ancestral splice region risk allele (C/T) were significantly and
differentially increased among the White and Hispanics cohorts.

The NPC1 gene and modifying genes with an independent association with BMI categories in the
White and Hispanic cohorts
The NPC1 gene, CAV1 gene, and modifying gene SNPs were analyzed to determine
independent association with BMI categories in the White and Hispanic cohorts (Table 2). The
three NPC1 gene ancestral genic risk alleles positioned at nucleotides 644 (A/G), 1926 (G/C), and
2572 (A/G) were significantly associated with increased odds ratios (1.96, 1.81, and 2.03,
respectively) for obesity category in the White cohort. However, the previous CAV1 gene ancestral
intron non-risk allele (T/C) was significantly associated with increased odds ratio (2.71) for
overweight category in the White cohort. Moreover, with respect to the modifying genes, the
LXR gene derived 5’ UTR risk allele (C/T), SREBP1c gene ancestral 3’ UTR risk allele (G/C),
and the previous SREBP1c gene derived splice region non-risk allele (C/T) were significantly
associated with increased odds ratios (2.26, 2.26, and 1.87, respectively) for obesity category in
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the White cohort, while the LXR gene ancestral promoter region risk allele (G/A) was borderline
significantly associated with an increased odds ratio (1.58) for obesity category in the White
cohort. Finally, the PGC1 gene derived intron risk allele (G/A) was significantly associated with
an increased odds ratio (2.59) for overweight category in the Hispanic cohort. Therefore, the
previous CAV1 ancestral intron non-risk allele (T/C) was significantly associated with overweight
category, while the previous SREBP1c gene derived spice region non-risk allele (C/T) was
significantly associated with obesity category in the White cohort.

The NPC1 gene and modifying genes with an independent association with HbA1c categories in
the White and Hispanic cohorts
The NPC1 gene, CAV1 gene, and modifying gene SNPs were analyzed to determine
independent association with HbA1c categories in the White and Hispanic cohorts (Table 3). The
NPC1 gene ancestral genic risk allele positioned at nucleotide 2572 (A/G) was significantly
associated with an increased odds ratio (1.94) for prediabetes category and also borderline
significantly associated with an increased odds ratio (2.07) for diabetes category in the Hispanic
cohort. Moreover, with respect to modifying genes, the previous PGC1 gene ancestral intron nonrisk allele (G/A) was borderline significantly associated with an increased odds ratio (1.73) for
prediabetes category, while also the LXR gene ancestral promoter region risk allele (G/A) was
borderline significantly associated with an increased odds ratio (1.82) the diabetes category in the
Hispanic cohort. Finally, the SREBP1c gene ancestral 3’ UTR risk allele (G/C) was significantly
associated with an increased odds ratio (3.37) for diabetes category, while the LXR gene ancestral
intron risk allele (G/A) was borderline significantly associated with an increased odds ratio (2.26)
for diabetes category in the White cohort. Therefore, the SREBP1c gene ancestral 3’ UTR risk
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allele (G/C) was independently and significantly associated with diabetes category in the White
cohort, while the NPC1 gene ancestral genic risk allele positioned at nucleotide 2572 (A/G) was
independently and significantly associated with prediabetes category in the Hispanic cohort.

The NPC1 gene and modifying gene interactions and association with BMI categories in the White
and Hispanic cohorts
The NPC1 gene and modifying gene SNP interactions were analyzed to determine
association with BMI categories in the White and Hispanic cohorts (Table 4). The NPC1 gene
ancestral genic risk allele positioned at nucleotide 1926 (G/C) interacted with the previous CAV1
gene ancestral intron non-risk allele (G/A) and was significantly associated with an increased odds
ratio (2.88) for obesity category in the White cohort. The NPC1 gene ancestral genic risk allele
positioned at nucleotide 644 (A/G) interacted with the SREBP1c gene ancestral splice region risk
allele (C/T) and was borderline significantly associated with an increased odds ratio (3.17) for
overweight category in the White cohort. Moreover, the NPC1 gene ancestral genic risk allele
positioned at nucleotide 2572 (A/G) interacted with the SREBP1c gene ancestral 3’ UTR risk allele
(G/C) and was borderline significantly associated with an increased odds ratio (3.54) for the
overweight category in the White cohort, while the same NPC1 gene ancestral genic risk allele
positioned at nucleotide 2572 (A/G) also interacted with the SREBP1c gene ancestral splice region
allele (C/T) and was significantly associated with an increased odds ratio (4.33) for overweight in
the White cohort. However, the NPC1 gene ancestral genic risk allele positioned at nucleotide
2572 (A/G) interacted with the LXR gene ancestral intron risk allele (G/A) and was significantly
associated with an increased odds ratio (5.14) for the overweight category in the Hispanic cohort.
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Moreover, the same NPC1 gene ancestral genic risk allele positioned at nucleotide 2572 (A/G)
interacted with both the previous SREBP1c gene derived 3’ UTR non-risk allele (G/C) and the
previous SREBP1c gene derived splice region non-risk allele (C/T) and was significantly
associated with increased odds ratios (12.44 and 11.10) for the overweight category in the Hispanic
cohort. Therefore, although the three deleterious (loss-of-function) NPC1 gene ancestral genic risk
alleles positioned at nucleotides 644 (A/G), 1926 (G/C), and 2572 (A/G) were independently and
significantly associated with the obesity category in the White cohort, an interaction with the
deleterious (loss-of-function) SREBP1c gene ancestral 3’ UTR risk allele (G/C) and the
deleterious (loss-of-function) SREBP1c gene ancestral splice region risk allele (C/T) was
significantly associated with the overweight category, suggesting a less functional NPC1 protein
interacts with less functional SREBP1c proteins decrease the BMI category (obesity to
overweight) in the White cohort. Similarly, although none of the three deleterious (loss-offunction) NPC1 gene ancestral genic risk alleles positioned at nucleotides 644 (A/G), 1926 (G/C),
and 2572 (A/G) were independently and significantly associated with either the overweight or
obesity categories in the Hispanic cohort, an interaction of the deleterious (loss-of-function) NPC1
gene ancestral genic risk allele positioned at nucleotide 2572 (A/G) with three modifying gene risk
alleles, including the deleterious (gain-of-function) LXR gene ancestral risk allele (G/A), the
non-deleterious SREBP1c gene derived 3’ UTR non-risk allele (G/C), and the non-deleterious
SREBP1c gene derived splice region non-risk allele (C/T) was significantly associated with the
overweight category, suggesting a less functional NPC1 protein interacts with a more functional
LXR protein and SREBP1c protein increase BMI category (normal to overweight) in the
Hispanic cohort.
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The NPC1 gene and modifying gene interactions and association with HbA1c categories in the
White and Hispanic cohorts
The NPC1 gene and modifying gene interactions were analyzed to determine association
with HbA1c categories in the White and Hispanic cohorts (Table 5). With respect to the White
cohort, the NPC1 gene ancestral genic risk allele positioned at nucleotide 644 (A/G) interacted
with the SREBP1c gene ancestral 3’ UTR risk allele (G/C) and was significantly associated with
an increased odds ratio (3.22) for the diabetes category. Moreover, the NPC1 gene ancestral genic
risk allele positioned at nucleotide 644 (A/G) interacted with the SREBP1c gene ancestral splice
region risk allele (C/T) and was significantly associated with an increased odds ratio (2.43) for the
prediabetes category and also significantly associated with an increased odds ratio (3.16) for the
diabetes category in the White cohort. The NPC1 gene ancestral genic risk allele positioned at
nucleotide 1926 (G/C) interacted with the LXR derived 5’ UTR risk allele (C/T) and was
significantly associated with an increased odds ratio (4.58) for the diabetes category in the White
cohort. Moreover, the NPC1 gene ancestral genic risk allele positioned at nucleotide 2572 (A/G)
interacted with the LXR derived 5’ UTR risk allele (C/T) and was significantly associated with
an increased odds ratio (2.71) for the prediabetes category and also significantly associated with
an increased odds ratio (2.20) for the diabetes category in the White cohort. Furthermore, the NPC1
gene ancestral genic risk allele positioned at nucleotide 2572 (A/G) interacted with the SREBP1c
gene ancestral 3’ UTR risk allele (G/C) and was significantly associated with an increased odds
ratio (2.63) for the prediabetes category and also borderline significantly associated with an
increased odds ratio (3.03) for the diabetes category in the White cohort. And finally with respect
to the White cohort, the NPC1 gene ancestral genic risk allele positioned at nucleotide 2572 (A/G)
interacted with the SREBP1c gene ancestral splice variant risk allele (C/T) and was significantly
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associated with an increased odds ratio (2.38) for the prediabetes category and also significantly
associated with an increased odds ratio (2.38) for the diabetes category. With respect to the
Hispanic cohort, the NPC1 gene ancestral genic risk allele positioned at nucleotide 644 (A/G)
interacted with the PCG1 gene derived intron risk allele (G/A) and was significantly associated
with an increased odds ratio (6.77) for the diabetes category. Moreover, the NPC1 gene ancestral
genic risk allele positioned at nucleotide 1926 (G/C) interacted with the CAV1 gene derived risk
allele (T/C) and was significantly associated with an increased odds ratio (2.87) for the prediabetes
category, and also the same NPC1 gene ancestral genic risk allele positioned at nucleotide 1926
(G/C) interacted with the CAV1 gene derived risk allele (G/A) and was both significantly
associated with an increased odds ratio (4.92 and 4.02) for the prediabetes and diabetes categories
in the Hispanic cohort. Therefore, although none of the three deleterious (loss-of-function) NPC1
gene ancestral genic risk alleles positioned at nucleotides 644 (A/G), 1926 (G/C), and 2572 (A/G)
were independently and significantly associated with either the prediabetes and diabetes category
in the White cohort, an interaction with the deleterious (gain-of-function) LXR gene derived 5’
UTR risk allele (C/T) and the LXR gene ancestral promoter risk allele (G/A), in addition to an
interaction with the deleterious (loss of function) SREBP1c gene ancestral 3’ UTR risk allele (G/C)
and the SREBP1c gene ancestral splice region risk allele (C/T), were significantly associated with
the prediabetes or diabetes categories, suggesting a less functional NPC1 protein interacts with
more functional LXR and LXR proteins and less functional SREBP1c proteins to increase the
HbA1c categories (normal to prediabetes or diabetes) in the White cohort. Moreover, although the
deleterious (loss-of-function) NPC1 gene ancestral genic risk allele positioned at nucleotide 1926
(G/C) was not independently and significantly associated the prediabetes or diabetes categories,
this particular gene risk allele interacted with the deleterious (loss-of-function) CAV1 gene derived
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intron risk alleles (T/C and G/A) in linkage-disequilibrium for significant association with the
prediabetes and diabetes categories with large odds ratios (4.0-5.0) in the Hispanic cohort.

Discussion
Heritability has long been a confounding phenomenon to demonstrate empirically.
Up to this point, phenotypes which are highly conserved between closely related individuals
have been difficult to explain fully using single nucleotide polymorphisms (SNPs) implicated by
genome wide analyses (GWAS) (24). These phenotypes range in anything from height and eye
color to cancer or obesity risk. The heritability that had long been described as “missing” or
“hidden” due to its phantom genetic presence is beginning to show itself. Common gene variants
are thought to interact via epistasis to generate phenotypes which are highly conserved
throughout generations of reproduction. These gene-gene interactions have small effect sizes
when considered singularly; but, when gene products encoded by these common variants
interact, the effect sizes can be greatly increased, thus explaining the heretofore elusive nature of
heredity (25). We have begun to uncover and explore the mechanisms that govern heritability.
We have shown that effect sizes are greatly increased when considering gene-gene interactions.
Also, the number of these interactions increases when stratifying for ethnicity, supporting the
idea that genetic background plays an important role in phenotypic outcomes. This largely
reduces the amount of empirically confounding heritability. Epistasis plays a large role in the
manifestation of individual genotype into an easily observable phenotype. This highlights the
biological power of microevolution (26). Relatively small changes in the genome can have huge
impacts on an organism’s overall fitness. This may be an underlying mechanism of the
overwhelmingly adept plasticity of humanity. Humans are able to adapt their genotype to fit the
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evolutionary environment (27). This work further emphasizes the importance of studying the
frequency changes of obesity risk variants throughout human evolution.
Furthermore, we have successfully translated the biochemical mechanism first discovered
in the NPC1+/- mouse model into a human cohort. We have identified gene-gene interactions that
support the hypothesis of a working NPC1 pathway that can differentially govern individual lipid
metabolism. This represents the final step in characterizing a candidate obesity gene. From our
work, NPC1 has become the best understood obesity candidate gene since FTO (28). The NPC1
pathway connects specific dietary components to genetically altered metabolism (Figure 3). A
diet high in saturated fatty acids upregulates PGC1α and PGC1β, which leads to increased
activation of LXR and RXR, which leads to increased expression of SREBP1c. NPC1 activity
feedback-inhibits processing and function of SREBP1c. We hypothesize that these human NPC1
risk alleles diminish NPC1 protein activity which interferes with this feedback inhibition. The
net result is a further increase in SREBP1c expression and activity. This causes increased
lipogenesis and storage of triacylglycerol by adipose tissue as well as a suppression of βoxidation and lipolysis. The SNP-SNP interactions we have reported likely work in conjunction
to amplify the deleterious effects of one another along the pathway. Their small individual effect
sizes are largely increased when interacting with other alleles. What we see, then, is a system
where small single nucleotide mutations can cause large scale metabolic changes. Rather than
requiring new genes to arise to modify phenotype, metabolism can be altered greatly by epistasis.
This, then is a system that can be finely tuned by natural selection relatively quickly. What is
likely is that these mutations were selected for in an environment where they were largely
beneficial, but, in our modern obesogenic environment, now pose a risk to increase likelihood of
disease (29).
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Conclusion
We have supplied evidence that the NPC1 pathway is functional in humans, as we have
previously reported in mice. Using a Southwestern United States cohort, we have found evidence
of epistasis contributing to high effect sizes of predisposition to obesity and diabetes. These
results cement NPC1’s pivotal role in regulation of whole-body lipid homeostasis, and further its
characterization as an obesity candidate gene. Our mouse work has been successfully translated
into furthered understanding of the mechanisms that govern human metabolism. We hope
increased knowledge of human genotypes and how they increase likelihood for undesired clinical
outcomes can affect change in dietary and behavioral patterns. Perhaps one day, genotypic
understanding will reach a point were an individual’s ideal diet and exercise regimen can be
determined with a simple DNA test. We will continue to further the knowledge of this particular
aspect of human metabolism in the hopes that it will contribute to the betterment and well-being
of so many people who suffer from the adverse effects of obesity and diabetes on a daily basis.
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Figure 1. Characterization of White and Hispanic cohorts. (A) percentage of individuals residing
in each BMI category (20.0-24.9, normal; 25.0-29.9, overweight; >30.0, obesity). (B) Percentage
of individuals residing in each hemoglobin A1c category (<5.7%, normal; 5.7-6.5%, prediabetic;
>6.5% diabetic). Asterisk denotes significant difference using Chi Square test (p-value < 0.05).
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Figure 2. Frequency of risk alleles among cohorts (A) Frequency of NPC1 and CAV1 risk
alleles. (B) Frequency of NPC1 pathway modifying gene risk alleles. Asterisk denotes significant
difference using Chi Square test (p-value < 0.05).
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Figure 3. Schematic representation of the NPC1 gene x nutrient metabolic pathway associated with
metabolic disease phenotypes. A: Dietary saturated fatty acids (palmitic acid and steric acid)
increase expression of the PGC1 gene and amounts of encoded PGC1 protein. B: The PGC1
protein serves as a transcriptional coactivator for the nuclear receptor LXR/ proteins (activated
in the presence of oxysterol) that form a heterodimer with RXR (activated in the presence of
retinoic acid) to increase expression of the SREBP1c gene and amounts of encoded precursor
SREBP1c protein. C: The NPC1 protein and CAV1 protein reported to physically interact and
regulate the transport of cholesterol and fatty acids from the lumen of late endosomes/lysosomes
to the endoplasmic reticulum promotes feedback inhibition of the SREBP pathway. D: The
increased amounts of PGC1 protein also serves as a transcriptional coactivator for the increased
amounts of mature SREBP1c protein to regulate expression of many genes the encode enzymes
involved in energy metabolism pathways. As reported in a previous study these energy metabolism
pathways include glycolysis and lipogenesis responsible for energy production and storage, in
addition to lipolysis and fatty acid -oxidation responsible for energy mobilization and production.
71

Finally, the NPC1 gene x nutrient metabolic pathway “point of interaction” is proposed to occur
at the intersect between steps C and D, where decreased NPC1 protein function prevents feedback
inhibition of the SREBP pathway and thus increases the proteolytic processing of increased
amounts of precursor SREBP1c protein to produce mature SREBP1c protein that regulates the
expression of diverse energy metabolism genes. PGC1, peroxisome-proliferator-activated
receptor gamma coactivator-1; LXR/, liver X receptor  and ; S, sterol; RXR, retinoid X
receptor; R, retinoic acid; NPC1, Niemann-Pick C1; CAV1, caveolin1; F, fatty acid; SREBP1c,
sterol regulatory element-binding protein 1c; LXRE, liver X receptor regulatory element; SRE,
sterol regulatory element.
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TABLE 1. The NPC1 gene, CAV1 gene, and modifying gene SNPs previously reported to be associated with
obesity and/or type 2 diabetes categories
Ancestral
Derived
Risk
Position
Functional
Gene
SNP
Alleles
Allele
Allele
Allele
and Type
Affect
NPC1

rs1805081

A/G

A

G

A+

H215R

D (N,L)

NPC1

rs1788799

G/C

G

C

G+

M642I

D (N,L)

NPC1

rs1805082

A/G

A

G

A+

I858V

D (N,L)

CAV1

rs926198

T/C

T

C

C+

Intron

D (L)

CAV1

rs3807989

G/A

G

A

A+

Intron

D (L)

LXRα

rs2695121

C/T

C

T

T+

5’ UTR

D (G)

LXRβ

rs35463555

G/A

G

A

G+

Promoter

D (G)

PGC1

rs11746690

G/A

G

A

A+

Intron

D (G)

SREBP1c

rs2297508

G/C

G

C

G+

3’ UTR

D (L)

SREBP1c

rs11868035

C/T

C

T

C+

Splice region

D (L)

Tabulation of previous single nucleotide polymorphisms (SNPs) used for genotype analysis of individuals to determine
association and interaction with BMI and HbA1c categories in the White and Hispanic cohorts. The risk allele with a plus
sign denotes a previous reported association with BMI or HbA1c category. Abbreviations: D, Deleterious; N, Neutral; L,
Loss-of-Function; G; Gain-of-Function.

73

TABLE 2. The NPC1 gene, CAV1 gene, and modifying gene SNP independent association with BMI category in
the White and Hispanic cohorts
Gene

SNP

Alleles

Risk Allele

BMI

Odds Ratio

P-value

White Cohort
NPC1

rs1805081

A/G

A

Obesity

1.98

0.0188*

NPC1

rs1788799

G/C

G+

Obesity

1.81

0.0367*

NPC1

rs1805082

A/G

A+

Obesity

2.03

0.0166*

CAV1

rs926198

T/C

T

Overweight

2.71

0.0048*

LXRα

rs2695121

C/T

T+

Obesity

2.26

0.0041*

LXRβ

rs35463555

G/A

G+

Obesity

1.58

0.0867

SREBP1c

rs2297508

G/C

G+

Obesity

2.26

0.0119*

SREBP1c

rs11868035

C/T

T

Obesity

1.87

0.0490*

Overweight

2.59

0.0159*

Hispanic Cohort
PGC1β

rs11746690

A+

G/A

Simple multinomial logistic regression was used to determine odds ratios belonging to BMI category for each denoted
gene risk allele stratified by the White (n = 160) and Hispanic (n = 143) cohorts. The risk allele with a plus sign denotes
a previous reported association with BMI or HbA1c category. An asterisk denotes a P-value less than 0.05. Odds ratios
with a P-value on the borderline of significance are included.
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TABLE 3. The NPC1 gene, CAV1 gene, and modifying gene SNP independent association with HbA1c category
in the White and Hispanic cohorts
Gene

SNP

Alleles

Risk Allele

HbA1C

Odds Ratio

P-value

White Cohort
LXRβ

rs35463555

G/A

G+

Diabetes

2.26

0.0710

SREBP1c

rs2297508

G/C

G+

Diabetes

3.37

0.0058*

Hispanic Cohort
NPC1

rs1805082

A/G

A+

Prediabetes

1.94

0.0417*

NPC1

rs1805082

A/G

A+

Diabetes

2.07

0.0582

PGC1β

rs11746690

G/A

G

Prediabetes

1.73

0.0667

LXRβ

rs35463555

G/A

G+

Diabetes

1.82

0.0869

Simple multinomial logistic regression was used to determine odds ratios belonging to HbA1c category for each denoted
gene risk allele stratified by the White (n = 160) and Hispanic (n = 143) cohorts. The risk allele with a plus sign denotes
previous reported association with BMI or HbA1c category. An asterisk denotes a P-value less than 0.05. Odds ratios
with a P-value on the borderline of significance are included.
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TABLE 4. The NPC1 gene, CAV1 gene, and modifying gene interaction and association with BMI category in
the White and Hispanic cohorts
Interacting Risk
Odds
Gene 1
SNP 1
Gene 2
SNP 2
BMI
P-value
Alleles 1 and 2
Ratio
White Cohort
NPC1

rs1788799

CAV1

rs3807989

G+ and G

Obesity

2.88

0.0389*

NPC1

rs1805081

SREBP1c

rs11868035

A+ and C+

Overweight

3.17

0.0709

NPC1

rs1805082

SREBP1c

rs2297508

A+ and G+

Overweight

3.54

0.0722

NPC1

rs1805082

SREBP1c

rs11868035

A+ and C+

Overweight

4.33

0.0102*

Hispanic Cohort
NPC1

rs1805082

LXRβ

rs35463555

A+ and G+

Overweight

5.14

0.0490*

NPC1

rs1805082

SREBP1c

rs2297508

A+ and C

Overweight

12.44

0.0116*

NPC1

rs1805082

SREBP1c

rs11868035

A+ and T

Overweight

11.10

0.0341*

Multiple multinomial logistic regression with an interaction term between two gene SNPs was used to determine odds
ratios belonging to BMI category for each denoted risk allele stratified by the White (n = 160) and Hispanic (n = 143)
cohorts. The risk allele with a plus sign denotes previous reported association with BMI or HbA1c category. An asterisk
denotes P-value less than 0.05. Odds ratios with a P-value on the borderline of significance are included.
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TABLE 5. The NPC1 gene, CAV1 gene, and modifying gene interactions with HbA1c category in the White and
Hispanic cohorts
Interacting Risk
Odds
Gene 1
SNP 1
Gene 2
SNP 2
HbA1c
P-value
Alleles 1&2
Ratio
White Cohort
NPC1

rs1805081

SREBP1c

rs2297508

A+ and G+

Diabetes

3.22

0.0459*

NPC1

rs1805081

SREBP1c

rs11868035

A+ and C+

Prediabetes

2.43

0.0379*

NPC1

rs1805081

SREBP1c

rs11868035

A+ and C+

Diabetes

3.16

0.0154*

NPC1

rs1788799

LXRα

rs2695121

G+ and T+

Diabetes

4.58

0.0189*

NPC1

rs1805082

LXRα

rs2695121

A+ and T+

Prediabetes

2.71

0.0293*

NPC1

rs1805082

LXRα

rs2695121

A+ and T+

Diabetes

2.20

0.0248*

NPC1

rs1805082

SREBP1c

rs2297508

A+ and G+

Prediabetes

2.63

0.0370*

NPC1

rs1805082

SREBP1c

rs2297508

A+ and G+

Diabetes

3.03

0.0513

NPC1

rs1805082

SREBP1c

rs11868035

A+ and C+

Prediabetes

2.38

0.0271*

NPC1

rs1805082

SREBP1c

rs11868035

A+ and C+

Diabetes

2.38

0.0324*

Hispanic Cohort
NPC1

rs1805081

PGC1β

rs11746690

T+ and A+

Diabetes

6.77

0.0373*

NPC1

rs1788799

CAV1

rs926198

G+ and C+

Prediabetes

2.87

0.0474*

NPC1

rs1788799

CAV1

rs3807989

G+ and A+

Prediabetes

4.92

0.0080*

NPC1

rs1788799

CAV1

rs3807989

G+ and A+

Diabetes

4.02

0.0251*

Multiple multinomial logistic regression with an interaction term between two gene SNPs was used to determine odds
ratios belonging to HbA1c category for each denoted risk allele stratified by Whites (n = 160) and Hispanics (n = 143).
The risk allele with a plus sign denotes a previous reported association with BMI or HbA1c category. An asterisk denotes
P-value less than 0.05. Odds ratios with a P-value on the borderline of significance are included.
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Abstract
It is generally accepted that the selection of gene variants during human evolution optimized
energy metabolism that now interacts with our obesogenic environment to increase the
prevalence of obesity. The purpose of this study was to perform a global evolutionary and
metabolic analysis of human obesity gene risk variants (110 human obesity genes with 127
nearest gene risk variants) identified using genome-wide association studies (GWAS) to enhance
our knowledge of early and late genotypes. As a result of determining the mean frequency of
these obesity gene risk variants in 13 available populations from around the world our results
provide evidence for the early selection of ancestral risk variants (defined as selection before
migration from Africa) and late selection of derived risk variants (defined as selection after
migration from Africa). Our results also provide novel information for association of these
obesity genes or encoded proteins with diverse metabolic pathways and other human diseases.
The overall results indicate a significant differential evolutionary pattern for the selection of
obesity gene ancestral and derived risk variants proposed to optimize energy metabolism in
varying global environments and complex association with metabolic pathways and other human
diseases. These results are consistent with obesity genes that encode proteins possessing a
fundamental role in maintaining energy metabolism and survival during the course of human
evolution.
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Introduction
The most recent report from the Centers for Disease Control and Prevention indicates that
16.9% of children and adolescents (2 to 19 years of age) and 34.9% of adults (20 years of age and
older) have obesity as defined by a body mass index ≥ the age adjusted 95 th percentile and ≥ 30
kg/m2, respectively (Ogden et al., 2014). To determine the molecular basis of common obesity that
has reached epidemic proportions in the United States and other developed countries, genomewide association studies (GWAS) have been performed to identify obesity gene risk variants that
increase susceptibility to this metabolic disease (Meyre et al., 2009; Speliotes et al., 2010;
Kilpelainen et al., 2011; Rouskas et al., 2012; Locke et al., 2015). These GWAS in addition to
subsequent transferability studies performed in different populations around the world have
confirmed the identity of 110 human obesity genes with 127 nearest obesity gene risk variants. It
is generally accepted that the obesity epidemic is a recent manifestation that has occurred during
the past few decades and not all individuals or populations are adversely affected, thereby
suggesting individual differences based on genetic variability and interactions with an obesogenic
environment (Nakamura et al., 2015; Nettleton et al., 2015; Reddon et al., 2016).
Consistent with obesity gene risk variants interacting with an obesogenic environment to
increase adiposity, James V. Neel proposed the thrifty genotype hypothesis based on positive
selection (adaptation) of “thrifty genes” resulting from seasonal food shortages and episodic
famines during the course of human evolution (Neel, 1962, 1999). Similarly, John R. Speakman
proposed the drifty genotype hypothesis based on neutral selection (genetic drift) of “drifty genes”
resulting from predation release characterized by liberation from predation pressures due to the
advent of fire and development of weapons, thereby increasing the upper limit of body weight set
points (Speakman, 2008, 2013). In support of these two hypotheses, commentaries indicate that
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both positive and neutral selection of obesity gene risk variants have occurred during human
evolution to optimize efficient storage of food energy for later use when food becomes limiting
(Wells, 2006; Prentice et al., 2008; Henneberg et al., 2014). It should also be noted, however, that
other studies have questioned the thrifty genotype hypothesis due to the high prevalence of obesity
within certain populations, such as in the South Pacific, whereby past seasonal food shortages and
episodic famines may not to have occurred (Gosling et al., 2015).
We propose that by considering the two main evolutionary environments that have
occurred in human history, those experienced by early hunter-gatherers and later by
agriculturalists, novel insight will be gained concerning the selection of obesity gene risk variants
(thrifty and drifty genotypes). Therefore, the purpose of this study was to perform a global analysis
of all known and validated human obesity gene risk variants (110 human obesity genes with 127
nearest gene risk variants) identified using GWAS from an evolutionary and metabolic perspective
to enhance our knowledge of early and late genotypes. When considering a nucleotide
polymorphism, there are usually two possible nucleotides found at a particular locus with one
being older when determined phylogenetically. When the polymorphism is analyzed for risk
association, the risk is assigned to one of the two nucleotides, the older nucleotide representing an
“ancestral risk variant” and the newer nucleotide representing a “derived risk variant”. Therefore,
as a result of determining the mean frequency of obesity gene ancestral and derived risk variants
in 13 available populations our results provide evidence for the early selection of ancestral risk
variants and late selection of derived risk variants. Our results also provide novel information for
the association of these obesity genes and encoded proteins that function in diverse metabolic
pathways and other human diseases. The overall results indicate a significantly differential
evolutionary pattern for selection of obesity gene ancestral and derived risk variants proposed to
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optimize energy metabolism in varying global environments and complex association of obesity
genes or encoded proteins with metabolic pathways and other human diseases. These results are
consistent with obesity genes that encode proteins possessing a basic and fundamental role in
maintaining energy metabolism and survival of humans during the course of human evolution.

Materials and methods
Sample data
The human obesity gene risk variants were identified from several GWAS (Meyre et al.,
2009; Speliotes et al., 2010; Kilpelainen et al., 2011; Rouskas et al., 2012; Locke et al., 2015). The
sample data consists of 110 human obesity genes (56 obesity genes with ancestral risk variants and
54 obesity genes with derived risk variants). For the 110 human obesity genes, there are a total of
127 nearest risk variants represented by 64 nearest ancestral risk variants (41 genic and 23
nongenic) and 63 nearest derived risk variants (42 genic and 21 nongenic). The human obesity
genes with ancestral risk variants (Supplementary material Table 1) and derived risk variants
(Supplementary material Table 2) are arranged according to the chromosomal cytogenic band
location. Additional information includes the chromosome number, allele pair (ancestral or derived
designation), risk variant, Fst (a measure of heterozygosity across populations), and variant
frequency in each population. The available population frequency for risk variants were collected
from the National Center for Biotechnical Information (NCBI) online database. There are 13
populations represented in the NCBI online database. The abbreviations for these 13 populations
are as follows: YRI, Yoruba in Ibadan, Nigeria (Sub-Saharan African); AFR, African American
descent from the Coriell Cell Repository; MKK, Maasai in Kinyawa, Kenya; ASW, African
ancestry in Southwest USA; JPT, Japanese in Tokyo, Japan; CHB, Han Chinese in Beijing; CEU,
Northern and Western European ancestry in Utah; GIH, Gujarati Indians in Houston, Texas; MEX,
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Mexican ancestry in Los Angeles, California; EUR, European American; CHD, Chinese ancestry
in Denver, Colorado; CHN, Chinese American descent from the Coriell Cell Repository; and TSI,
Tuscans in Italy.

Chromosomal ideogram of obesity genes
The chromosomal loci for the 100 human obesity genes are provided using a chromosomal
ideogram. The ideogram was generated using the tools available on the on-line NCBI genome
decoration page (http://www.ncbi.nlm.nih.gov/genome/tools/gdp).
Population gene variant frequencies
The human obesity gene risk variant frequencies in 13 available populations were collected
and statistical means were calculated and graphed using box and whisker plots for the ancestral
and derived risk variants. With respect to the box and whisker plots, the middle horizontal line
within boxes represents the mean frequency, the boxes represent plus and minus one standard
deviation, and the whiskers represent the upper and lower range. A significant difference of mean
frequency is indicated by different letters among populations. The graph for obesity gene ancestral
risk variants was arranged according to decreasing mean frequency in 13 available populations.
The identical order of these populations was thereafter maintained for all subsequent graphs to
allow direct comparison between mean frequencies of risk variants. All population gene variant
frequencies were tested by one-way ANOVA to determine whether or not any of the 13 population
means were significantly dissimilar, followed by each population being compared to all of the
other populations using a t-test (two-sample assuming unequal variances) to determine statistically
significantly different means by voiding the null hypothesis of similar means.
Gene variant composite of multiple signals
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The chromosomal loci of obesity gene risk variants were compared to regions of
chromosomes determined to be of high value with regard to the composite multiple signals (CMS)
technique for haplotype scoring (Grossman et al., 2010). The CMS takes into account length of
the haplotype region, the frequency of any neighboring ancestral or derived gene variants
compared to that expected for genetic drift, and the difference between gene variant frequencies
in other populations. Any obesity gene risk variants located within a region to be of high CMS
value is noted as to which population was observed having a high CMS score at that locus (because
of the fact that CMS hotspots vary from population to population due to divergent evolutionary
history). The 110 gene variants were compared to CMS hotspots for 4 available populations
indicated by Northern and Western European ancestry in Utah (CEU), Yoruba in Ibadan (YRI),
Japanese in Tokyo (JPT), and Han Chinese in Beijing (HCB).

KEGG Mapper database
The Kyoto Encyclopedia of Genes and Genomes (KEGG) Mapper database
(http://genome.jp/kegg) was developed to provide an assessment for association of genes with
metabolic pathways and human diseases (Kanehisa et al., 2000; Kanehisa et al., 2016). The obesity
genes were queried using the KEGG Mapper database and associations among obesity genes with
ancestral risk variants or derived risk variants were organized in descending order based on the
number of hits.
Heterozygosity among populations
The Fst was calculated across all populations represented in this study. This value is used
to determine the difference between the observed heterozygosity and what is to be expected based
on Hardy-Weinberg equilibrium (Wright, 1950).
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Results
Chromosomal ideogram of obesity genes
The chromosomal loci for the 100 obesity genes are provided using a chromosomal
ideogram (Fig. 1). The obesity genes with ancestral and derived risk variants were distributed
among most of the 22 chromosomes on both p and q regions. The X and Y chromosomes had no
obesity genes.
Obesity gene ancestral risk variant frequencies
The obesity gene risk variant frequencies in 13 available populations were combined and
resulting statistical means, standard deviation, and range were determined and displayed using box
and whisker plots for the ancestral risk variants. First, with respect to the total 64 ancestral risk
variants, the Yoruba in Ibadan (YRI) had significantly higher mean frequencies compared to other
populations except for the population of African American descent (AFR) (Fig. 2A). The
remaining populations were not significantly different from each other except for Tuscans in Italy
(TSI). Second, with respect to the 41 ancestral risk variants within genic regions, the four
populations of African or African American descent (YRI, AFR, MKK, and ASW) had
significantly higher mean frequencies compared to the remaining populations (Fig 2B). Third, with
respect to the 23 ancestral risk variants within nongenic regions, the Yoruba in Ibadan (YRI) had
significantly higher mean frequencies compared to other populations except for two populations
of African or African American descent (AFR and MKK) (Fig. 2C). Finally, it should be noted
that for the populations of African or African American descent (YRI, AFR, MKK, and ASW) the
standard deviations and ranges were noticeably smaller compared to other populations. Therefore,
these results provide evidence of early (prior to human migration from Africa) selection of obesity
gene ancestral obesity risk variants.
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Obesity gene derived risk variant frequencies
The obesity gene risk variant frequencies in 13 available populations were combined and
resulting statistical means, standard deviation, and range were determined and displayed using box
and whisker plots for the derived risk variants. First, with respect to the total 63 derived risk
variants, the Yoruba in Ibadan (YRI) had significantly lower mean frequencies compared to other
populations except for the other populations of African and African American descent (AFR,
MKK, and ASW) (Fig. 3A). The remaining populations were not significantly different from each
other except for Northern and Western European ancestry in Utah (CEU) and Tuscans in Italy
(TSI). Second, with respect to the 42 ancestral risk variants within genic regions, the four
populations of African or African American descent (YRI, AFR, MKK, and ASW) had
significantly lower mean frequencies compared to the remaining populations (Fig 3B). The
remaining populations were not significantly different from each other except for Northern and
Western European ancestry in Utah (CEU). Third, with respect to the 21 derived risk variants
within nongenic regions, the population of Yoruba in Ibadan (YRI) and African American (AFR)
had significantly lower mean frequencies compared to other populations except for two of the
other populations of African descent (MKK and ASW) (Fig. 3C). Finally, again it should be noted
that for the populations of African or African American descent (YRI, AFR, MKK, and ASW) the
standard deviations and ranges were noticeably smaller compared to other populations. Therefore,
these results provide evidence of late (after human migration from Africa) selection for obesity
gene derived obesity risk variants.
Gene variant composite of multiple signals
The chromosomal loci of obesity gene risk gene variants were compared to regions of
chromosomes within populations determined to be of high value with regard to the composite of
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multiple signals (CMS) for haplotype scoring. With respect to the 127 obesity gene risk variants
evaluated in this study, only 1 obesity gene risk variant was found to be located within a
chromosomal region determined to have high a CMS score. The obesity gene risk variant is an
ancestral variant (PDXDCI, rs4985155) known to represent a CMS chromosomal hotspot for the
population of Yoruba in Ibadan (YRI). This result supports evidence of selection for the ancestral
risk variant prior to human migration from Africa.
KEGG Mapper database
The obesity genes with ancestral risk variants queried using the KEGG Mapper database
resulted in a total of 76 hits associated with metabolic pathways and human diseases (Table 1).
With respect to the first category denoted as “metabolism” that provides the most pertinent
information in understanding the basis of obesity, 6 hits were noted for carbohydrate and lipid
metabolism (starch and sucrose metabolism, adipocyte lipolysis), regulation of energy metabolism
(insulin secretion and signaling) and different forms of diabetes mellitus (type II diabetes mellitus
and insulin resistance) known to represent a disease of energy metabolism. In contrast, the obesity
genes with derived risk variants queried using the KEGG Mapper database resulted in a total of
146 hits associated with metabolic, cellular, and homeostatic pathways and human diseases (Table
2). Again, with respect to the first category denoted as “metabolism” that provides the most
pertinent information in understanding the basis of obesity, 35 hits were involved in food digestion
(pancreatic secretion, gastric acid secretion, salivary secretion, bile secretion), regulation of energy
metabolism (glucagon signaling, insulin secretion and signaling), and lipid and steroid metabolism
(aldosterone synthesis, adipocyte lipolysis, steroid hormone synthesis, fatty acid elongation,
synthesis of unsaturated fatty acids, thyroid hormone synthesis), and insulin resistance. Therefore,
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these results indicated that obesity genes with ancestral and derived risk variants have some
overlapping yet distinct differences in association with metabolic pathways and human diseases.
Heterozygosity among populations
With respect to all obesity gene risk variants the results indicated that none of the
populations displayed heterozygosity (measured by Fst) thereby indicating Hardy-Weinberg
disequilibrium. Moreover, none of the populations were displayed differences in heterozygosity
between either ancestral or derived risk variants (data not shown).

Discussion
The selection of obesity gene risk variants during human evolution has honed the efficiency
of our digestion, absorption, and assimilation of macronutrients to optimize energy metabolism
and increase the storage of energy for later use when food becomes limiting. However, since most
developed populations no longer experience seasonal food shortages and episodic famines, these
obesity gene risk variants now interact with our obesogenic environment, characterized by energy
dense foods and a sedentary lifestyle, to increase the prevalence of obesity (Chakravarthy et al.,
2004). The purpose of this study was to perform a global analysis of all known and validated
human obesity gene risk variants (110 human obesity genes with 127 nearest gene risk variants)
identified using GWAS from an evolutionary and metabolic perspective to enhance our knowledge
of early and late genotypes. Therefore, as a result of determining the mean frequency of obesity
gene ancestral and derived risk variants in 13 available populations, our results provide evidence
for the early selection of ancestral risk variants and late selection of derived risk variants. Our
results also provide novel information for the association of these obesity genes or encoded
proteins that function in diverse metabolic pathways and other human diseases. The overall results
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indicate a significantly differential evolutionary pattern for selection of obesity gene ancestral and
derived risk variants proposed to optimize energy metabolism in varying global environments and
complex association of obesity genes or encoded proteins with metabolic pathways and other
human diseases. These results are consistent with obesity genes that encode proteins possessing a
fundamental role in maintaining energy metabolism and survival of humans during the course of
human evolution.
To begin our discussion, it is important to consider what factors other than seasonal food
shortages and episodic famines may have contributed to the selection of obesity gene risk variants.
With respect to obesity gene ancestral risk variants selected early in human evolution, it has been
reported that hunter-gatherers stalked prey in a manner similar to wolves, which is referred to as
endurance hunting, in procuring food energy to survive and reproduce (Prentice, 2001; Bramble
et al., 2004; Prentice et al., 2005; Lieberman, 2014). This method of hunting involves the
meticulous and persistent tracking of prey that eventually becomes exhausted after running for
hours in the heat of day. Once the prey becomes exhausted, the hunter could more easily sacrifice
the animal to obtain a rich source of food energy. The enhanced ability of hunter-gatherers to
utilize endurance hunting, which required a highly efficient use of stored energy in the form of
triacylglycerol, is believed to have been acquired through selection among early humans and
consistent with obesity gene ancestral risk variants. Moreover, after human migration from Africa
into cooler climate regions which may not have been conducive to endurance hunting, humans
developed other methods for hunting, such as advanced weaponry and horseback riding that
reduced selective pressures acting upon obesity gene ancestral risk variants, thereby decreasing
frequency of these risk variants due to genetic drift. Nonetheless, the relatively high frequency of
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obesity gene ancestral risk variants remaining among modern humans in our current obesogenic
environment contributes to the obesity epidemic.
Seasonal food shortages and episodic famines are also believed to have occurred later in
human evolution (100,000-40,000 years ago) and particularly after dawning of the agricultural era
(within ~12,000 years ago) as a result of frequent catastrophic crop failures causing selection of
obesity gene derived risk variants that optimized energy storage in these different environmental
conditions (Prentice et al., 2005). While some have argued that the mortality occurring during
these periods of food shortage and episodic famine may not have been severe enough to select for
derived risk variants, others contend that decreased fertility may have been a strong enough
selective force to generate pressure for the increase in population frequency of derived risk variants
(Prentice et al., 2008; Speakman, 2008). Since selective pressures must have varied among
different populations in the form of numerous chronologically and geologically separated events,
different obesity gene derived risk variants were selected for, thus differing in frequency from one
population to another. Moreover, further evidence that endurance hunting initially selected for
obesity gene ancestral risk variants is illustrated by populations that subsequently depended on
agricultural methods for millennia, such as the Europeans, who now have a significantly lower
frequency of these obesity gene ancestral risk variants compared to individuals from sub-Saharan
Africa. As stated above, the selection for obesity gene ancestral and derived risk variants during
human evolution is now believed to be a hindrance for individuals living in our modern obesogenic
environment due to an interaction between an energy rich diet and sedentary lifestyle, resulting in
the heightened ability to store and maintain energy. Further evidence indicates that obesity gene
risk variants may interact with other obesity gene risk variants and/or modifying gene risk variants
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through epistasis to influence population differences in the prevalence in obesity (Casazza et al.,
2011).
With regard to the CMS metric used in our study only the PDXDC1 obesity gene was
identified. The ancestral risk variant located in a region of high CMS score was identified in the
population from Yoruba in Ibadan (YRI), thereby supporting the hypothesis that this obesity gene
ancestral risk variant was selected during the hunter-gatherer era of human development. It should
also be noted that not all of the obesity gene ancestral and derived risk variants, which reside in
both coding and noncoding regions, may represent the actual causal variants. This is due to the
fact that these ancestral and derived risk variants were identified using GWAS which may have
detected variants in linkage disequilibrium with the causal variants nearby on the same
chromosome (Hagg et al., 2015). However, the likelihood that none of these variants can be
described as causal is unlikely. An in-depth investigation of each gene and associated risk variant
would ultimately be necessary to determine causality. Continued investigation of these obesity
gene ancestral and derived gene risk variants identified using GWAS remains important since they
are candidates for causal variants and, at least, act as a reflection of the linked causal variants.
Recent advances in the emerging fields of epigenetics, whole genome sequencing, and genome
editing, along with other available technologies, must be used to identify the causal variants and
physiological mechanisms responsible for predisposition to obesity (Claussnitzer et al., 2015; Wu
et al., 2016). It is likely that the list of obesity gene variants will grow as more genomic data from
other populations becomes available (Southam et al., 2009).
In conclusion, our study provides an evolutionary and metabolic perspective of obesity
genes with ancestral and derived risk variants that model early and late genotypes suspected to
interact with the obesogenic environment to increase adiposity and weight gain responsible for the
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current obesity epidemic. As a result of determining the mean frequency of obesity gene ancestral
and derived risk variants in 13 available populations, our results provide evidence for the early
selection of ancestral risk variants (before migration from Africa) and late selection of derived risk
variants (after migration from Africa).
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Figures

Figure 1. Chromosomal ideogram of human obesity genes. The chromosomal loci for the 110
obesity genes are provided using a chromosomal ideogram. The obesity genes with ancestral risk
variants are localized adjacent to chromosomal loci denoted by gray arrowheads, whereas the
obesity genes with derived risk variants are localized adjacent to chromosomal loci denoted with
black arrowheads.
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Figure 2. Obesity gene ancestral risk variant frequencies. Box and whisker plots represent the mean
frequency, standard deviation, and range of obesity gene ancestral risk variant frequencies in 13
available populations. The middle horizontal lines within boxes represent the mean frequency,
99

boxes represent plus and minus one standard deviation, and the whiskers represent the range. A
significant difference for the mean frequency of a population is indicated by different lower case
letters. (A) Total obesity gene ancestral risk variant frequencies (64 variants), (B) Genic obesity
gene ancestral risk variant frequencies (41 variants), (C) Nongenic obesity ancestral risk variant
frequencies (23 variants). The abbreviations for 13 populations are as follows: YRI, Yoruba in
Ibadan, Nigeria (Sub-Saharan African); AFR, African American descent from the Coriell Cell
Repository; MKK, Maasai in Kinyawa, Kenya; ASW, African ancestry in Southwest USA; JPT,
Japanese in Tokyo, Japan; CHB, Han Chinese in Beijing; CEU, Northern and Western European
ancestry in Utah; GIH, Gujarati Indians in Houston, Texas; MEX, Mexican ancestry in Los
Angeles, California; EUR, European American; CHD, Chinese ancestry in Denver, Colorado;
CHN, Chinese American descent from the Coriell Cell Repository; and TSI, Tuscans in Italy.

100

Figure 3. Obesity gene derived risk variant frequencies. Box and whisker plots represent the mean
frequency, standard deviation, and range of obesity gene ancestral risk variant frequencies in 13
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available populations. The middle horizontal lines within boxes represent the mean frequency,
boxes represent plus and minus one standard deviation, and the whiskers represent the range. A
significant difference for the mean frequency of a population is indicated by different lower case
letters. (A) Total obesity gene derived risk variant frequencies (63 variants), (B) Genic obesity
gene derived risk variant frequencies (42 variants), (C) Nongenic obesity derived risk variant
frequencies (21 variants). The abbreviations for 13 populations are as follows: YRI, Yoruba in
Ibadan, Nigeria (Sub-Saharan African); AFR, African American descent from the Coriell Cell
Repository; MKK, Maasai in Kinyawa, Kenya; ASW, African ancestry in Southwest USA; JPT,
Japanese in Tokyo, Japan; CHB, Han Chinese in Beijing; CEU, Northern and Western European
ancestry in Utah; GIH, Gujarati Indians in Houston, Texas; MEX, Mexican ancestry in Los
Angeles, California; EUR, European American; CHD, Chinese ancestry in Denver, Colorado;
CHN, Chinese American descent from the Coriell Cell Repository; and TSI, Tuscans in Italy.
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Table 1. Human obesity genes with ancestral risk variants
Pathway and/or disease phenotype

Hits

Metabolism
Adipocytokine signaling pathway

2

Pathway and/or disease phenotype

Hits

Tuberculosis

1

Amoebiasis

1

Metabolic pathways

1

Endometrial cancer

1

Insulin signaling pathway

1

Colorectal cancer

1

Regulation of lipolysis in adipocytes

1

Insulin resistance

1

Development / Homeostasis

Type II diabetes mellitus

1

Melanogenesis

2

Non-alcoholic fatty liver disease

1

Th1 and Th2 cell differentiation

1

Starch and sucrose metabolism

1

Aldosterone synthesis and secretion

1

Aldosterone-regulated NA reabsorption

1

Spliceosome

1

Pathways in cancer

2

PI3K-Akt signaling pathway

3

Transcriptional misregulation in cancer

2

cAMP signaling pathway

3

Huntington's disease

2

Ubiquitin mediated proteolysis

2

Basal cell carcinoma

2

mTOR signaling pathway

2

Proteoglycans in cancer

2

MAPK signaling pathway

2

Inflammatory bowel disease

2

Cell adhesion molecules

2

Rheumatoid arthritis

1

mRNA surveillance pathway

1

Salmonella infection

1

Hippo signaling pathway

1

Thyroid cancer

1

Lysosome

1

Prostate cancer

1

Protein processing in ER

1

Cocaine addiction

1

ErbB signaling pathway

1

Hepatitis B

1

NOD-like receptor signaling pathway

1

Legionellosis

1

Calcium signaling pathway

1

Toxoplasmosis

1

cGMP-PKG signaling pathway

1

Breast cancer

1

Prolactin signaling pathway

1

Alcoholism

1

Wnt signaling pathway

1

Parkinson's disease

1

NF-kappa B signaling pathway

1
1

Pathology/ Infection

Cell signaling / maintenance

Malaria

1

Cytokine-cytokine receptor interaction

Influenza A

1

Phagosome

1

Pertussis

1

FoxO signaling pathway

1

Leishmaniasis

1

Adherens junction

1

MicroRNAs in cancer
Arrhythmogenic right ventricular
cardiomyopathy
Chagas disease

1

Hedgehog signaling pathway

1

1

Rap1 signaling pathway

1

1

Toll-like receptor signaling pathway

1

Acute myeloid leukemia

1

Gap junction

1

Measles

1

Longevity regulating pathway

1

Pathogenic Escherichia coli infection

1

AMPK signaling pathway

1

Tuberculosis

1

Oxytocin signaling pathway

1

Amoebiasis

1

Endocytosis

1

Endometrial cancer

1

Jak-STAT signaling pathway

1

Colorectal cancer
1
HIF-1 signaling pathway
1
The KEGG Mapper database was developed to provide an assessment for association of genes with
metabolic pathways and human diseases.
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Table 2. Human obesity genes with derived risk variant associated pathways
Pathway and/or disease phenotype

Hits

Metabolism

Pathway and/or disease phenotype

Hits

Development / Homeostasis

Metabolic pathways

4

Osteoclast differentiation

3

Aldosterone synthesis and secretion

4

Circadian entrainment

3

Purine metabolism

3

Melanogenesis

2

Insulin secretion

2

Oocyte meiosis

1

Vasopressin-regulated water reabsorption

2

Progesterone-mediated oocyte maturation

1

Thyroid hormone synthesis

2

Th17 cell differentiation

1

Regulation of lipolysis in adipocytes

2

Vascular smooth muscle contraction

1

Insulin resistance

1

Renin secretion

1

Glucagon signaling pathway

1

Platelet activation

1

Pyrimidine metabolism

1

Ribosome

1

Endocrine resistance

1

Ovarian steroidogenesis

1

Pancreatic secretion

1

GnRH signaling pathway

1

Fatty acid metabolism

1

Natural killer cell mediated cytotoxicity

1

Bile secretion

1

Dorso-ventral axis formation

1

Fatty acid elongation

1

Th1 and Th2 cell differentiation

1

Amino and nucleotide sugar metabolism

1

Calcium reabsorption

1

Cell signaling / maintenance

Nicotinate and nicotinamide metabolism

1

cAMP signaling pathway

3

Salivary secretion

1

Neurotrophin signaling pathway

3

Mucin type O-glycan biosynthesis

1

Longevity regulating pathway

3

Biosynthesis of unsaturated fatty acids

1

Neuroactive ligand-receptor interaction

3

Gastric acid secretion

1

Estrogen signaling pathway

2

Steroid hormone biosynthesis

1

Rap1 signaling pathway

2

Cholinergic synapse

2

Pathology/ Infection

MAPK signaling pathway

2
2

HTLV-I infection

3

Ras signaling pathway

Non-small cell lung cancer

3

Adrenergic signaling

2

Huntington's disease

2

cGMP-PKG signaling pathway

2

Alcoholism

2

Chemokine signaling pathway

2

Pathways in cancer

2

AMPK signaling pathway

2

Cocaine addiction

2

PI3K-Akt signaling pathway

2

Small cell lung cancer

2

EGFR tyrosine kinase inhibitor resistance

1

Viral carcinogenesis

2

FoxO signaling pathway

1

Tuberculosis

2

Tight junction

1

Herpes simplex infection

1

Regulation of TRP channels

1

Measles

1

HIF-1 signaling pathway

1

Hepatitis B

1

Gap junction

1

Fanconi anemia pathway

1

TNF signaling pathway

1

Inflammatory bowel disease

1

Jak-STAT signaling pathway

1

Endometrial cancer

1

Endocannabinoid signaling

1

Dilated cardiomyopathy

1

Cell adhesion molecules

1

Salmonella infection

1

Glutamatergic synapse

1

Influenza A

1

Calcium signaling pathway

1

Morphine addiction

1

Prolactin signaling pathway

1

Chagas disease

1

Oxytocin signaling pathway

1

Amphetamine addiction

1

Ubiquitin mediated proteolysis

1
1

Leishmaniasis

1

Antigen processing and presentation

Prostate cancer

1

Endocytosis

1

MicroRNAs in cancer

1

Phospholipase D signaling pathway

1
1

Toxoplasmosis

1

Dopaminergic synapse

Vibrio cholerae infection

1

Lysosome

1

GABAergic synapse

1

Cytokine-cytokine receptor interaction
1
The KEGG Mapper database was developed to provide an assessment for association of genes with
metabolic pathways and human diseases.
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Chapter 5: The Evolution of an Obesity Gene

Endurance Hunting Hypothesis
Over the course of human development, as we diverged from apes and began to walk upright, we gained the ability to hunt for prey in a manner similar to wolves, known as cursorial or
endurance hunting. This manner of hunting involves the meticulous and persistent tracking of
prey until the prey becomes exhausted by the hours of running in the African heat of day. Once
the prey is exhausted, it can be easily killed. This method of hunting requires the hunter’s
endurance outlast that of its prey. A strong selective pressure on generating a phenotype that can
endure long periods of caloric expenditure without exhaustion must have exerted itself on early
man as he began this strategy. Dr. Bramble and Dr. Lieberman document the importance of
endurance running (ER) in shaping modern man [1]. In this groundbreaking work, the
researchers compare the kinematics and biomechanics of human ER compared to other
locomotive mammals. What they show is that humans are incredibly efficient at undertaking ER.
We have been shaped to specialize in this one form of locomotion. Our skeleton, muscles, and
thermoregulation all show signs of adaptations to accommodate for the stresses and requirements
of being endurance runners. While the thrifty gene hypothesis proposed by James Neel sites
famine as the selective force (a force that exists on all species at one time or another in their
evolutionary history), this scenario elucidates a selective pressure that is unique to humans that
takes place very early in our descent from apes [2]. Evidence for this may exist in the fact that an
ancestral NPC1 risk associated SNP (M642I) becomes the predominant form of the gene after
our divergence from apes (Figure 1). A more in-depth analysis of this change is given later.
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This ER hypothesis takes into account both the thrifty phenotype hypothesis and the
“drifty” gene hypothesis in that the selection pressure exerted by cursorial hunting is sexually
dimorphic. Only the males of early human ancestors would pursue the prey, while the females
would stay near the tribal home, thus imparting selective pressure on only the males’ endurance
capabilities. Sexually dimorphic selection in a genetically correlated trait leads to a slower rate of
evolution [3]. This would explain why the selective pressure proposed here did not lead to
saturation of the alleles associated with weight gain in our evolutionary history. Therefore, the
males were developing a thrifty genotype (or more appropriately an extreme endurance
genotype) while the females were undergoing the drifty genotype mechanism, where the
selective pressures are not subjected to their genome directly; but, changes in frequency are due
to the successful men having increased number of progeny. This hypothesis is at least
preliminarily supported by unpublished data we have gathered regarding the NPC1 SNPs
association with BMI. When cohorts are stratified by gender, these associations are only
observed in males, not females. This data cannot be published from the cohorts we have now,
due to the number of subjects being too low for statistical power calculations. More research is
needed to further corroborate these findings.
The endurance genotype developed under the selective pressure of cursorial hunting
made humans into a highly efficient energy user, capable of utilizing resources at an efficient
rate. It, therefore, translates that when modern man is in an environment where he no longer has
to traverse vast distances in order to obtain rich food sources, and yet retains the extreme
endurance genotype, he will be unable to properly maintain body weight. This will inevitably
lead to obesity. A recent study on the effect of high levels of physical activity in overcoming
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SNP risk allele effects suggests that when these genes are used as potentially designed, obesity
rates are diminished [4].

The unique predominant human Npc1 haplotype
At some point after the divergence of humans and apes, the missense mutation of
isoleucine to methionine at the 642nd residue became the predominantly expressed form of the
NPC1 protein. All other mammals predominantly express the 642-isoleucine-encoding Npc1
allele. The methionine-encoding allele at this residue has been associated with a risk for obesity
in humans [5]. The mechanisms for this shift in allele frequency are debatable. Was the NPC1
protein with a methionine at the 642nd residue advantageous for the human expressing it?
Assuming a functional deficiency in the novel NPC1 protein bestowing a slower rate lipid
trafficking, perhaps the carrier of this allele was able to maintain a lipid stores for longer
durations, outlasting those who did not carry the allele during a famine or, more likely based on
our work of ancestral obesity risk alleles, was more fit for endurance hunting. Whether this is a
product of the decrease in the probability of predation [6], or this is a product of the success of
hunter-gatherer or agriculturalist methods diminishing the probability of a food supply failure, or
a combination of the two, is unclear [7]. What is clear is that if this allele alters the gene-diet
interaction of its carrier, then it was most certainly under some form of selective pressure at
some points during its evolutionary history, whether it be positive or negative or both [8]. More
specifically, if methionine 642 alters the mechanistic efficiency of NPC1 allowing its possessor
to maintain fat stores longer, he and his kin will potentially outlast a competitor lacking this
allele during a famine or be able to run a few miles farther than the prey he is tracking, ensuring
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his success. On the other hand, a pre-human mammal that is subject to predation has selective
pressure to avoid an overly obese phenotype. An allele that predisposes its possessor to an
overweight phenotype will be selected against in this scenario. This particular “thrifty” genotype,
then, can be explained as coming into existence due to the lack of predation, selecting against
overweight phenotype, combined with the success of emerging sustenance-collecting behaviors
specific to hominid development. The problem with these assumptions is that recent work has
shown that there is no evidence to support evolutionarily-novel recurrent famine in huntergatherer societies to suggest the necessity of a new thrifty gene [9]. This further strengthens the
argument for ER as the predominant selective pressure for early human metabolism.
Furthermore, predation release is known to make other animals more abundant and have a larger
overall body size (gigantism), not increase adipose tissue mass [10]. This would not cause the
observed effects of increasing risk for obesity.

The agricultural revolution and the dawn of the modern obesogenic environment
In the millennia after the emergence of Homo sapiens in Africa, the migration of man
throughout Europe and Asia and the Americas took place (100,000 to 10,000 years ago).
Concurrent with the most recent era of this migration, was the emergence of the agricultural
revolution. This brought with it two selective pressures: the increase in crop-failure-based famine
[11], and the change in diet from a predominantly wild animal and plant based hunter-gatherer
diet to a wheat, starch, and dairy based pastoral diet [12]. The former, and arguably the most
acute selective pressure, aligns with the hypothesis Neel originally proposed. In these times of
crop failure, when calories are scarce or non-existent, it is easy to imagine that humans with a
metabolism that allowed them to more slowly utilize their fat stores would have a distinct
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advantage over those individuals that quickly burned through theirs. Alternatively, if a person’s
metabolism allows them to store more fat when calories are plentiful, then they would have the
same advantage when a famine occurs: longer lasting fat-stores [13]. What Neel could not have
known is that this was not due to a thrifty gene, but a thrifty genotype: a polymorphic collection
of nucleotides across a wide swath of genes working together to alter metabolism, able to quickly
change in frequency due to microevolutionary mechanisms. We can see that the frequency of
NPC1 risk variants decreases after the migration from Africa (Figure 2). This would support the
hypothesis that these ancestral risk variants were no longer in the evolutionary environment that
selected them, therefore they are undergoing genetic drift. Meanwhile, derived risk variants
increase after the human migration from Africa (Chapter 4), suggesting that this new agricultural
environment selected new variants encoding new metabolic and phenotypic changes.
The second selective pressure brought on by the agricultural revolution was the change in
dietary sources of sustenance. A non-Western immigrant eating a Western diet has higher risk of
metabolic disease compared to Western counterparts [14], [15]. This appears to be evidence that
there are selective pressures involved in relying on a new diet. In turn, this implies that there are
genotypes that are more fit for certain diets than others. Famous instances of this being the case
are well documented, such as the lactase persistence mutation in Europeans [16] to benefit from
pastoral milk sources, and the amylase gene copy number increase to take advantage of starch
agricultural sources [17]. It is clear, from these examples, that the European genome has had
time to adapt to the diet provided by agriculture. It is, therefore, likely that the same genome and
that of any other population whose ancestors relied on agriculture for many, many generations,
has had time to adapt to the famine that is a part of the agricultural lifestyle. From this
knowledge, and the work we have done with gene-gene interactions along the NPC1 pathway, it
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is clear that understanding what genotypes interact well with what dietary macronutrients will be
an important step forward in combating modern metabolic diseases. If we were able to genotype
a patient and tell them exactly which specific dietary sources to avoid in order to lower their risk
of developing or abate their already presenting weight gain or insulin resistance, we would be
able to make a huge impact on health outcomes.

Conclusion
Our understanding of NPC1 as an obesity candidate gene has grown tremendously over
the last 5 years. We have taken a gene that was targeted by GWAS as being associated with
increased risk for elevated BMI, generated a mouse model, discovered a metabolic mechanism,
translated the mechanism back to humans, and furthered the understanding of that gene’s place
in humanity’s evolution, as well as the understanding of phantom or hidden heritability. Our
work has filled a gap that many researchers like to discuss as being the counter point to the
importance of obesity gene candidacy. In the process we have made NPC1 the most wellcharacterized obesity gene to date. Hopefully, one day our work will better the lives of every
human who has suffered from obesity or diabetes, or help their children avoid the same fate.
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Figure 1. Alignment of amino acid sequence of the NPC1 protein demonstrating the
unique predominant human mutation M642I

Figure 2. Frequencies for risk associated NPC1 alleles in global populations
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